<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS One</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40009584</article-id><article-id pub-id-type="pmc">PMC11864521</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0310410</article-id><article-id pub-id-type="publisher-id">PONE-D-23-20544</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Breast Tumors</subject><subj-group><subject>Breast Cancer</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Metastasis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Basic Cancer Research</subject><subj-group><subject>Metastasis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Treatment</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Computer and Information Sciences</subject><subj-group><subject>Artificial Intelligence</subject><subj-group><subject>Machine Learning</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>Medical Risk Factors</subject><subj-group><subject>Cancer Risk Factors</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Risk Factors</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Mathematical and Statistical Techniques</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Forecasting</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Forecasting</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Applied Mathematics</subject><subj-group><subject>Algorithms</subject><subj-group><subject>Machine Learning Algorithms</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Simulation and Modeling</subject><subj-group><subject>Algorithms</subject><subj-group><subject>Machine Learning Algorithms</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Computer and Information Sciences</subject><subj-group><subject>Artificial Intelligence</subject><subj-group><subject>Machine Learning</subject><subj-group><subject>Machine Learning Algorithms</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Lung and Intrathoracic Tumors</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Machine learning-based prediction of distant metastasis risk in invasive ductal carcinoma of the breast</article-title><alt-title alt-title-type="running-head">Machine learning-based prediction of distant metastasis risk in invasive ductal carcinoma of the breast</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dong</surname><given-names>Jingru</given-names></name><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="aff001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Lei</surname><given-names>Ruijiao</given-names></name><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Feiyang</given-names></name><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="aff001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Lu</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="aff001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Lanlan</given-names></name><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="aff001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Shangzhi</given-names></name><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><xref rid="aff001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Yunhua</given-names></name><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="aff001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Jialin</given-names></name><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="aff001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Wenwen</given-names></name><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><xref rid="aff001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Haixia</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><xref rid="aff001" ref-type="aff"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0009-9234-2502</contrib-id><name><surname>Zhang</surname><given-names>Li</given-names></name><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><xref rid="cor001" ref-type="corresp">*</xref><xref rid="aff001" ref-type="aff"/></contrib></contrib-group><aff id="aff001">
<addr-line>Shihezi University Medical College School of Medical College, Shihezi University, Shihezi, Xinjiang, China</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Rabiei</surname><given-names>Reza</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>Shahid Beheshti University of Medical Sciences, ISLAMIC REPUBLIC OF IRAN</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>zl491191385@163.com</email></corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue>2</issue><elocation-id>e0310410</elocation-id><history><date date-type="received"><day>2</day><month>7</month><year>2023</year></date><date date-type="accepted"><day>31</day><month>8</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Dong et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Dong et al</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0310410.pdf"/><abstract><p>More than 90% of deaths due to breast cancer (BC) are due to metastasis-related complications, with invasive ductal carcinoma (IDC) of the breast being the most common pathologic type of breast cancer and highly susceptible to metastasis to distant organs. BC patients who develop cancer metastases are more likely to have a poor prognosis and poor quality of life, so it is extremely important to recognize and diagnose whether distant metastases have occurred in IDC as early as possible. In this study, we develop a non-invasive breast cancer classification system for detecting cancer metastasis. We used Anaconda-Jupyter notebooks to develop various Python programming modules for text mining, data processing, and machine learning (ML) methods. A risk prediction model was constructed based on four algorithms: Random Forest, XGBoost, Logistic Regression, and SVM. Additionally, we developed a hybrid model based on a voting mechanism using these four algorithms as the base models. The models were compared and evaluated by the following metrics: accuracy, precision, recall, F1-score, and area under the ROC curve (AUC) values. The experimental results show that the hybrid model based on the voting mechanism exhibits the best prediction performance (accuracy: 0.867, precision: 0.929, recall: 0.805, F1-score: 0.856, AUC: 0.94). This stable risk prediction model provides a valuable reference support for doctors in assessing and diagnosing the risk of IDC hematogenous metastasis. It also improves the work efficiency of doctors and strives to provide patients with increased chances of survival.</p></abstract><funding-group><funding-statement>This work was financially supported by the Shihezi University Research Program Project, the fund number is:BJZK202404.</funding-statement></funding-group><counts><fig-count count="9"/><table-count count="9"/><page-count count="21"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>The original data for this study comes from the SEER database. However, in our research, the data obtained from SEER has been stored in an online at <ext-link xlink:href="https://figshare.com/articles/dataset/_/24996902" ext-link-type="uri">https://figshare.com/articles/dataset/_/24996902</ext-link>, allowing readers easier access to the data.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>The original data for this study comes from the SEER database. However, in our research, the data obtained from SEER has been stored in an online at <ext-link xlink:href="https://figshare.com/articles/dataset/_/24996902" ext-link-type="uri">https://figshare.com/articles/dataset/_/24996902</ext-link>, allowing readers easier access to the data.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>1 Introduction</title><p>Breast cancer (BC) is the most common malignant tumor and the main cause of cancer-related deaths in women worldwide [<xref rid="pone.0310410.ref001" ref-type="bibr">1</xref>]. The World Health Organization (WHO) International Agency for Research on Cancer (IARC) released the global cancer burden data in 2020 [<xref rid="pone.0310410.ref002" ref-type="bibr">2</xref>], and the latest statistical report data show that the number of new cases of BC worldwide has exceeded 2.26 million, exceeding the number of cases of lung cancer for the first time. BC has thus been crowned the world&#x02019;s No. 1 cancer, replacing lung cancer, which had been top of the list for many years [<xref rid="pone.0310410.ref002" ref-type="bibr">2</xref>]. In recent years, the incidence and mortality rates of female BC have been increasing yearly, and the proportion of incidence and mortality of all malignant tumors in women has also increased [<xref rid="pone.0310410.ref003" ref-type="bibr">3</xref>], which seriously affects women&#x02019;s physical and mental health. It is projected that by the year 2040, the number of breast cancer patients will increase to 4.07 million, with 1.4 million fatalities [<xref rid="pone.0310410.ref004" ref-type="bibr">4</xref>].</p><p>Despite the good therapeutic results and prognosis achieved in the treatment of early-stage BC, the prognosis of patients with metastatic BC is still poor. More than 90% of deaths in patients with BC are not caused by the primary tumor but by distant metastasis of the primary tumor [<xref rid="pone.0310410.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0310410.ref006" ref-type="bibr">6</xref>]. Infiltrating Ductal Carcinoma (IDC) is the most common subtype among BC, accounting for about 80% of all BC cases [<xref rid="pone.0310410.ref007" ref-type="bibr">7</xref>]. IDC is also the most common form of invasive BC. This pathologic tissue type of BC has a poor prognosis and is highly susceptible to axillary lymph node and distant organ metastases, and the five-year survival rate of patients with distant metastasis from invasive ductal carcinoma is only 27.4%. Therefore, early detection of distant metastasis in BC can help develop individualized treatment plans, which has specific significance for predicting patient survival time and improving patient prognosis [<xref rid="pone.0310410.ref008" ref-type="bibr">8</xref>]. Cancer metastasis risk assessment is important to reduce overall BC mortality. Appropriate risk assessment is a major factor in BC management that determines patient survivability [<xref rid="pone.0310410.ref009" ref-type="bibr">9</xref>].</p><p>The successful introduction of information and communication technologies (ICT) in medical practice is an important stake in the renovation of the health system and more precisely in cancer care [<xref rid="pone.0310410.ref010" ref-type="bibr">10</xref>]. With the development of artificial intelligence, machine learning has shown a very strong data mining ability and has been applied to all walks of life. Machine learning is a field that focuses on the learning aspect of artificial intelligence by developing algorithms that best represent a set of data to guide computers to learn from the data and then make the best decisions and predictions based on the results of data analysis [<xref rid="pone.0310410.ref011" ref-type="bibr">11</xref>]. Combining machine learning with medical problems and integrating this development, more intelligent auxiliary diagnosis methods can be proposed to increase treatment time and cure opportunities for patients. In recent years, machine learning has proven to be of great value in BC diagnosis and survival, prognosis prediction, and other aspects [<xref rid="pone.0310410.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0310410.ref013" ref-type="bibr">13</xref>]. The use of machine learning algorithms to predict the survival risk of BC is currently a research hotspot at the intersection of artificial intelligence and medicine [<xref rid="pone.0310410.ref014" ref-type="bibr">14</xref>].</p><p>Although some BC prediction models based on the SEER database have been developed previously (<xref rid="pone.0310410.t001" ref-type="table">Table 1</xref>), few studies have attempted to use the ML algorithm to predict the risk of distant IDC transfers. In this study, machine learning algorithms was used instead of traditional statistical analysis methods to process the clinical characteristics data of patients with IDC, and a machine learning-based predictive model was developed to discover the relationship between certain independent variables and the likelihood of patients with IDC developing distant organ metastasis. Focusing on the predictive models of four algorithms: Logistic Regression, SVM, Random Forest and XGBoost, and using them as base models for integration to construct hybrid models. A ten-fold cross-validation was used to compare the accuracy, recall, precision, and AUC value of each model to predict the risk of cancer metastasis in patients with IDC, thereby assisting clinicians in making more rational clinical decisions and enabling patients to receive treatment earlier, which is useful for breast surgeons to quickly and accurately determine whether cancer metastasis has occurred in patients with IDC.</p><table-wrap position="float" id="pone.0310410.t001"><object-id pub-id-type="doi">10.1371/journal.pone.0310410.t001</object-id><label>Table 1</label><caption><title>Comparison of information on predicting survival outcomes or metastasis of cancer patients using machine learning algorithms in the past.</title></caption><alternatives><graphic xlink:href="pone.0310410.t001" id="pone.0310410.t001g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Authors</th><th align="center" rowspan="1" colspan="1">Prediction model</th><th align="center" rowspan="1" colspan="1">Objective</th><th align="center" rowspan="1" colspan="1">Result</th></tr></thead><tbody><tr><td align="justify" rowspan="1" colspan="1">Ahmad et al., 2022 [<xref rid="pone.0310410.ref015" ref-type="bibr">15</xref>]</td><td align="justify" rowspan="1" colspan="1">NB, SVM, MLP, J 48 and RF.</td><td align="justify" rowspan="1" colspan="1">A 10-fold cross validation was used.</td><td align="justify" rowspan="1" colspan="1">NB gave the best accuracy. 97.3%.</td></tr><tr><td align="justify" rowspan="1" colspan="1">Islam et al., 2020 [<xref rid="pone.0310410.ref016" ref-type="bibr">16</xref>]</td><td align="justify" rowspan="1" colspan="1">SVM, KNN, RF, ANN, and LR</td><td align="justify" rowspan="1" colspan="1">A 10-fold cross validation was employed.</td><td align="justify" rowspan="1" colspan="1">ANN yielded the highest accuracy. 98.57%.</td></tr><tr><td align="justify" rowspan="1" colspan="1">Choudhury et al., 2021 [<xref rid="pone.0310410.ref017" ref-type="bibr">17</xref>]</td><td align="justify" rowspan="1" colspan="1">MLP, VP, CC, KLR, SGD, AdaBoost, VFDT, SVM</td><td align="justify" rowspan="1" colspan="1">To diagnose and predict the cancer prognosis of Malignant Pleural Mesothelioma as early as possible (MPM).</td><td align="justify" rowspan="1" colspan="1">AdaBoost have the highest accuracy. 71.29%.</td></tr><tr><td align="justify" rowspan="1" colspan="1">Alfian et&#x000a0;al., 2022 [<xref rid="pone.0310410.ref018" ref-type="bibr">18</xref>]</td><td align="justify" rowspan="1" colspan="1">SVM</td><td align="justify" rowspan="1" colspan="1">Predicting Breast Cancer from Risk Factors Using SVM and Extra-TreesBased Feature Selection Method.</td><td align="justify" rowspan="1" colspan="1">80.23%</td></tr><tr><td align="justify" rowspan="1" colspan="1">Afolayan et&#x000a0;al., 2022 [<xref rid="pone.0310410.ref019" ref-type="bibr">19</xref>]</td><td align="justify" rowspan="1" colspan="1">DT</td><td align="justify" rowspan="1" colspan="1">Breast cancer detection using particle swarm optimization and decision tree machine learning technique.</td><td align="justify" rowspan="1" colspan="1">92.26%</td></tr><tr><td align="justify" rowspan="1" colspan="1">Seo et&#x000a0;al., 2022 [<xref rid="pone.0310410.ref020" ref-type="bibr">20</xref>]</td><td align="justify" rowspan="1" colspan="1">SVM</td><td align="justify" rowspan="1" colspan="1">Scaling multi-instance support vector machine to breast cancer detection on the BreaKHis dataset</td><td align="justify" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">Ak et al., 2020 [<xref rid="pone.0310410.ref021" ref-type="bibr">21</xref>]</td><td align="justify" rowspan="1" colspan="1">LR</td><td align="justify" rowspan="1" colspan="1">A comparative analysis of breast cancer detection and diagnosis using data visualization and machine learning applications.</td><td align="justify" rowspan="1" colspan="1">98.1%</td></tr><tr><td align="justify" rowspan="1" colspan="1">Sharma and Mishra et al., 2022 [<xref rid="pone.0310410.ref022" ref-type="bibr">22</xref>]</td><td align="justify" rowspan="1" colspan="1">Voting classifier</td><td align="justify" rowspan="1" colspan="1">Performance analysis of machine learning based optimized feature selection approaches for breast cancer diagnosis.</td><td align="justify" rowspan="1" colspan="1">99.41%</td></tr><tr><td align="justify" rowspan="1" colspan="1">Binsaif N et al., 2022 [<xref rid="pone.0310410.ref023" ref-type="bibr">23</xref>]</td><td align="justify" rowspan="1" colspan="1">RF</td><td align="justify" rowspan="1" colspan="1">Application of Machine Learning Models to the Detection of Breast Cancer.</td><td align="justify" rowspan="1" colspan="1">83.3%</td></tr></tbody></table></alternatives></table-wrap><p>Our contributions include (i) the use of machine learning algorithms instead of traditional statistical regression methods to process clinical characterization data of patients with IDC to identify patients at high risk of cancer metastasis. (ii) This paper compares several algorithms that can be used to process patient data and determines that a fusion model based on a voting mechanism is the best way to process the data. (iii) It provides a scientific basis and reference for doctors to formulate personalized diagnosis and treatment plans and decisions for patients with different survival prediction results, thus improving treatment outcomes; (iv) It provides a useful reference for the formulation and modification of medical policies.</p></sec><sec id="sec002"><title>2 System model and methods</title><sec id="sec003"><title>2.1 Data acquisition</title><p>The data used in this experiment were obtained using SEER*stat software (version 8.4.0.1, National Cancer Institute, United States) based on the Surveillance, Epidemiology, and End results (SEER) database, using the "International Classification of Oncological Diseases, Third Edition (ICD-O-3).&#x0201d; The inclusion criteria were (<xref rid="pone.0310410.g001" ref-type="fig">Fig 1</xref>): (1) tumor location: site recode ICD-O-3 for breast; (2) pathologic tissue ICD-O-3 staging of 8500/3 (invasive ductal carcinoma); (3) tumor staging using the 8th edition of the American Joint Committee of Cancer (AJCC) TNM staging criteria; (4) availability of complete clinical, pathologic and follow-up data. The exclusion criteria were: (1) missing or unknown disease-related information; (2) age &#x0003c;28 years or &#x0003e;75 years; (3) unknown information such as T, N, and M staging, race, grading, marital status, chemotherapy status, and radiotherapy status; and (4) incomplete follow-up information.</p><fig position="float" id="pone.0310410.g001"><object-id pub-id-type="doi">10.1371/journal.pone.0310410.g001</object-id><label>Fig 1</label><caption><title>Data inclusion and exclusion process.</title></caption><graphic xlink:href="pone.0310410.g001" position="float"/></fig></sec><sec id="sec004"><title>2.2 Data pre-processing</title><p>Data mining and analysis in this study were done by Python (version 3.10, Python Software Foundation) and SPSS (version 23, IBM, USA). For data preprocessing: (1) Read the dataset: after screening the dataset, there were no missing, abnormal, or duplicated data; (2) Since the positive and negative samples were extremely unbalanced among the included ending variables, this study chose to introduce the function RandomUnderSampler() used to randomly undersample the data from the imblearn library, and resample the data so that the positive to negative sample ratio was 1:1; (3) The categorical feature variables are dummy coded and converted into dummy variables; (4) The data are randomly split into training and test sets in a ratio of 7:3 using train_test_split() in scikit-learn; (5) The transformed dataset is normalized using StandardScaler() to remove the inter-variable scale relationships; (6) Univariate analyses were performed to compare variables between patients who had or had not developed cancer metastases. For categorical data, the chi-square test was used; for continuous non-normally distributed data, the Wilcoxon rank sum test was used. Multivariate logistic regression was performed for variables with P &#x0003c; 0.05 in univariate analysis to determine which variables were strongly associated with the development of metastases. Effective data preprocessing is the prerequisite basis for model building and training.</p></sec><sec id="sec005"><title>2.3 Model establishment</title><p>The training and testing procedures of the machine learning models were demonstrated in the JupyterNotebook environment using Python. Python sklearn and pandas software packages were used for data analysis, and Python matplotlib and seaborne were used to draw graphics. The basic modelling process is illustrated in <xref rid="pone.0310410.g002" ref-type="fig">Fig 2</xref>. The experimental environment configuration and the details of the software packages used for model development are shown in Tables <xref rid="pone.0310410.t002" ref-type="table">2</xref> and <xref rid="pone.0310410.t003" ref-type="table">3</xref>, and the list of abbreviations is shown in <xref rid="pone.0310410.t004" ref-type="table">Table 4</xref>.</p><fig position="float" id="pone.0310410.g002"><object-id pub-id-type="doi">10.1371/journal.pone.0310410.g002</object-id><label>Fig 2</label><caption><title>Modeling flowchart.</title></caption><graphic xlink:href="pone.0310410.g002" position="float"/></fig><table-wrap position="float" id="pone.0310410.t002"><object-id pub-id-type="doi">10.1371/journal.pone.0310410.t002</object-id><label>Table 2</label><caption><title>Experimental environment configuration table.</title></caption><alternatives><graphic xlink:href="pone.0310410.t002" id="pone.0310410.t002g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Hardware Environment</th><th align="center" rowspan="1" colspan="1">Software Environment</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">CPU Inter Corel i5&#x02013;6300hq</td><td align="center" rowspan="1" colspan="1">Windows 10</td></tr><tr><td align="center" rowspan="1" colspan="1">GPU GTX960m</td><td align="center" rowspan="1" colspan="1">Python 3.10</td></tr><tr><td align="center" rowspan="1" colspan="1">RAM 8GB</td><td align="center" rowspan="1" colspan="1">PyCharm2021.3.3</td></tr></tbody></table></alternatives></table-wrap><table-wrap position="float" id="pone.0310410.t003"><object-id pub-id-type="doi">10.1371/journal.pone.0310410.t003</object-id><label>Table 3</label><caption><title>Detailed information on software packages used for machine learning model development.</title></caption><alternatives><graphic xlink:href="pone.0310410.t003" id="pone.0310410.t003g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Package name</th><th align="center" rowspan="1" colspan="1">Version</th><th align="center" rowspan="1" colspan="1">Description</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Numpy</td><td align="center" rowspan="1" colspan="1">1.25.0</td><td align="left" rowspan="1" colspan="1">Numpy is the fundamental package for array computing with python</td></tr><tr><td align="center" rowspan="1" colspan="1">Pandas</td><td align="center" rowspan="1" colspan="1">2.1.0</td><td align="left" rowspan="1" colspan="1">Powerful data structures for data analysis, time series, and statistics</td></tr><tr><td align="center" rowspan="1" colspan="1">Matplotlib</td><td align="center" rowspan="1" colspan="1">3.5.1</td><td align="left" rowspan="1" colspan="1">Python plotting package</td></tr><tr><td align="center" rowspan="1" colspan="1">Sklearn</td><td align="center" rowspan="1" colspan="1">0.22.0</td><td align="left" rowspan="1" colspan="1">A set of python modules for machine learning and data mining</td></tr><tr><td align="center" rowspan="1" colspan="1">Imblearn</td><td align="center" rowspan="1" colspan="1">0.11.0</td><td align="left" rowspan="1" colspan="1">Toolbox for imbalanced dataset in machine learning</td></tr><tr><td align="center" rowspan="1" colspan="1">Seaborn</td><td align="center" rowspan="1" colspan="1">0.12.2</td><td align="left" rowspan="1" colspan="1">It provides a high-level interface for drawing attractive and informative statistical graphics.</td></tr><tr><td align="center" rowspan="1" colspan="1">XGBoost</td><td align="center" rowspan="1" colspan="1">1.2.0</td><td align="left" rowspan="1" colspan="1">XGBoost python package</td></tr></tbody></table></alternatives></table-wrap><table-wrap position="float" id="pone.0310410.t004"><object-id pub-id-type="doi">10.1371/journal.pone.0310410.t004</object-id><label>Table 4</label><caption><title>List of abbreviations.</title></caption><alternatives><graphic xlink:href="pone.0310410.t004" id="pone.0310410.t004g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Full noun name</th><th align="center" rowspan="1" colspan="1">Abbreviation</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Accuracy</td><td align="center" rowspan="1" colspan="1">ACC</td></tr><tr><td align="center" rowspan="1" colspan="1">Area under ROC curve</td><td align="center" rowspan="1" colspan="1">AUC</td></tr><tr><td align="center" rowspan="1" colspan="1">Logistic Regression</td><td align="center" rowspan="1" colspan="1">LR</td></tr><tr><td align="center" rowspan="1" colspan="1">Support Vector Machine</td><td align="center" rowspan="1" colspan="1">SVM</td></tr><tr><td align="center" rowspan="1" colspan="1">EXtreme Gradient Boosting</td><td align="center" rowspan="1" colspan="1">XGBoost</td></tr><tr><td align="center" rowspan="1" colspan="1">Invasive Ductal Carcinoma</td><td align="center" rowspan="1" colspan="1">IDC</td></tr><tr><td align="center" rowspan="1" colspan="1">Random Forest</td><td align="center" rowspan="1" colspan="1">RF</td></tr><tr><td align="center" rowspan="1" colspan="1">Machine Learning</td><td align="center" rowspan="1" colspan="1">ML</td></tr></tbody></table></alternatives></table-wrap><p>Support Vector Machine (SVM) is a supervised learning algorithm whose basic model is a maximally spaced linear classifier defined on the feature space, and whose basic idea is to maximize the marginal distance between the decision hyperplane and the instances closest to the boundary, with the aim of finding the optimal hyperplane that distinguishes between two different classes [<xref rid="pone.0310410.ref024" ref-type="bibr">24</xref>, <xref rid="pone.0310410.ref025" ref-type="bibr">25</xref>].</p><p>Logistic Regression (LR) is used to predict the probability of an event occurring by establishing a logistic function (<xref rid="pone.0310410.e001" ref-type="disp-formula">Eq 1</xref>) relationship between two or more predictor variables and an outcome variable, i.e., fitting the data to the logistic function. The Sigmoid function introduces a nonlinear element, so it can deal with 0/1 classification problems, and is often used to predict and discriminate the likelihood of a category or event [<xref rid="pone.0310410.ref026" ref-type="bibr">26</xref>, <xref rid="pone.0310410.ref027" ref-type="bibr">27</xref>].</p><disp-formula id="pone.0310410.e001">
<alternatives><graphic xlink:href="pone.0310410.e001.jpg" id="pone.0310410.e001g" position="anchor"/><mml:math id="M1" display="block" overflow="scroll"><mml:mi>f</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:mi>z</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:math></alternatives>
<label>(1)</label>
</disp-formula><p>Random Forest (RF) is a bagging integrated learning algorithm that uses a randomly selected subset of training samples and variables to generate multiple decision trees, each of which is a classifier that produces a classification result. By forming a large number of trees into a random forest, the risk of overfitting is reduced and the error converges to some generalized value [<xref rid="pone.0310410.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0310410.ref028" ref-type="bibr">28</xref>, <xref rid="pone.0310410.ref029" ref-type="bibr">29</xref>]. The pseudo code of the machine learning model is shown in <xref rid="pone.0310410.t005" ref-type="table">Table 5</xref>, and the basic learner parameters are shown in <xref rid="pone.0310410.t006" ref-type="table">Table 6</xref>.</p><table-wrap position="float" id="pone.0310410.t005"><object-id pub-id-type="doi">10.1371/journal.pone.0310410.t005</object-id><label>Table 5</label><caption><title>Pseudocode for machine learning models.</title></caption><alternatives><graphic xlink:href="pone.0310410.t005" id="pone.0310410.t005g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Algorithm: Logistic Regression</th></tr></thead><tbody><tr><td align="justify" rowspan="1" colspan="1">Step1: For i = 1 to n.</td></tr><tr><td align="justify" rowspan="1" colspan="1">Step2: For each data instance, calculate the regression value.</td></tr><tr><td align="justify" rowspan="1" colspan="1">Step3: Apply the Sigmoid function to each of obtained regression calculated values.</td></tr><tr><td align="justify" rowspan="1" colspan="1">Step4: Finalize the class labels and weights.</td></tr><tr><td align="justify" rowspan="1" colspan="1">Step5: Classify, If (<italic toggle="yes">P</italic>&#x0003e;0.5) assign label &#x02018;1&#x02019;otherwise, assign label &#x02018;0&#x02019;.</td></tr><tr><td align="center" rowspan="1" colspan="1">Algorithm:Linear SVM</td></tr><tr><td align="left" rowspan="1" colspan="1">Input: Data samples {x<sub>i</sub>,y<sub>i</sub>}, i = 1,2,.&#x000a0;.&#x000a0;.,n, where x<sub>i</sub>&#x02208;R<sup>d</sup>, y<sub>i</sub>&#x02208;{-1,+1}.</td></tr><tr><td align="left" rowspan="1" colspan="1">Output: Parameters &#x003c9;*, b* and categorical decision function of the categorical hyperplane.</td></tr><tr><td align="left" rowspan="1" colspan="1">Step1: Construct the objective optimization function:<break/><inline-formula id="pone.0310410.e002"><alternatives><graphic xlink:href="pone.0310410.e002" id="pone.0310410.e002g" position="anchor"/><mml:math id="M2" display="inline" overflow="scroll"><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">z</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">L</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:munder><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:munder></mml:mstyle><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x003b1;</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x003b1;</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi mathvariant="normal">y</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi mathvariant="normal">y</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:munderover></mml:mstyle><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x003b1;</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula><break/><inline-formula id="pone.0310410.e003"><alternatives><graphic xlink:href="pone.0310410.e003" id="pone.0310410.e003g" position="anchor"/><mml:math id="M3" display="inline" overflow="scroll"><mml:mi mathvariant="normal">s</mml:mi><mml:mo>.</mml:mo><mml:mi mathvariant="normal">t</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:munderover></mml:mstyle><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x003b1;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi mathvariant="normal">y</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula><break/>&#x003b1;<sub>i</sub> &#x02265; 0 (i = 1,2,&#x02026;,n)</td></tr><tr><td align="justify" rowspan="1" colspan="1">Step2: Find the value of the &#x003b1;-vector with the smallest value of the objective optimization function &#x003b1;* vector;</td></tr><tr><td align="left" rowspan="1" colspan="1">Step3: Calculate the corresponding coefficients &#x003c9;*.<break/><inline-formula id="pone.0310410.e004"><alternatives><graphic xlink:href="pone.0310410.e004" id="pone.0310410.e004g" position="anchor"/><mml:math id="M4" display="inline" overflow="scroll"><mml:msup><mml:mrow><mml:mi mathvariant="normal">&#x003c9;</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:munderover></mml:mstyle><mml:mrow><mml:msub><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">&#x003b1;</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi mathvariant="normal">y</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula></td></tr><tr><td align="left" rowspan="1" colspan="1">Step4: Find all S sample points that satisfy &#x003b1;<sub>s</sub> &#x0003e; 0 {x<sub>s</sub>, y<sub>s</sub>}, i.e., support vectors, and compute the corresponding parameters b<sub>s</sub>* and all b<sub>s</sub>* of all bs and the average value of all b<sub>s</sub>* b*.<break/><inline-formula id="pone.0310410.e005"><alternatives><graphic xlink:href="pone.0310410.e005" id="pone.0310410.e005g" position="anchor"/><mml:math id="M5" display="inline" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi mathvariant="normal">b</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">y</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi mathvariant="normal">n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:munderover></mml:mstyle><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x003b1;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mi mathvariant="normal">y</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula><break/><inline-formula id="pone.0310410.e006"><alternatives><graphic xlink:href="pone.0310410.e006" id="pone.0310410.e006g" position="anchor"/><mml:math id="M6" display="inline" overflow="scroll"><mml:msup><mml:mrow><mml:mi mathvariant="normal">b</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:mfrac><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:munderover></mml:mstyle><mml:mrow><mml:msubsup><mml:mrow><mml:mi mathvariant="normal">b</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula></td></tr><tr><td align="left" rowspan="1" colspan="1">Step5: Output categorical decision function f(x).<break/><inline-formula id="pone.0310410.e007"><alternatives><graphic xlink:href="pone.0310410.e007" id="pone.0310410.e007g" position="anchor"/><mml:math id="M7" display="inline" overflow="scroll"><mml:mi mathvariant="normal">f</mml:mi><mml:mo>(</mml:mo><mml:mi mathvariant="normal">x</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mo>(</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="normal">&#x003c9;</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup><mml:mi mathvariant="normal">x</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="normal">b</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula></td></tr><tr><td align="center" rowspan="1" colspan="1">Algorithm: Random Forest</td></tr><tr><td align="left" rowspan="1" colspan="1">Input: The data sample training set S = {x<sub>i</sub>, y<sub>i</sub>}, i = 1,2,.&#x000a0;.&#x000a0;., n, where x<sub>i</sub>&#x02208;R<sup>d</sup>, y<sub>i</sub>&#x02208; {-1,+1}, and the number of iterations of the base classifier T.</td></tr><tr><td align="left" rowspan="1" colspan="1">Output: The final strong classifier f(x).</td></tr><tr><td align="justify" rowspan="1" colspan="1">Step1: Perform bootstrap sampling on the original training set S to generate a new training set S<sub>i</sub>;</td></tr><tr><td align="justify" rowspan="1" colspan="1">Step2: Randomly extract a portion of features from S<sub>i</sub> and train the t-th decision tree model. Each tree has no pruning process and grows to the specified tree depth;</td></tr><tr><td align="justify" rowspan="1" colspan="1">Step3: The category with the highest number of votes from the T base classifiers is voted as the final category of the sample to be tested.</td></tr></tbody></table></alternatives></table-wrap><table-wrap position="float" id="pone.0310410.t006"><object-id pub-id-type="doi">10.1371/journal.pone.0310410.t006</object-id><label>Table 6</label><caption><title>Base learner parameters.</title></caption><alternatives><graphic xlink:href="pone.0310410.t006" id="pone.0310410.t006g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Model name</th><th align="center" rowspan="1" colspan="1">parameter</th></tr></thead><tbody><tr><td align="center" rowspan="6" colspan="1">Random Forest</td><td align="center" rowspan="1" colspan="1">N_jobs = 1</td></tr><tr><td align="center" rowspan="1" colspan="1">N_estimators = 500</td></tr><tr><td align="center" rowspan="1" colspan="1">Max_depth = 6</td></tr><tr><td align="center" rowspan="1" colspan="1">Min_samples_leaf = 2</td></tr><tr><td align="center" rowspan="1" colspan="1">Max_features = &#x02018;sqrt&#x02019;</td></tr><tr><td align="center" rowspan="1" colspan="1">Verbose = 0</td></tr><tr><td align="center" rowspan="2" colspan="1">SVM</td><td align="center" rowspan="1" colspan="1">Kernel = &#x02018;linear&#x02019;</td></tr><tr><td align="center" rowspan="1" colspan="1">C = 0.025</td></tr><tr><td align="center" rowspan="6" colspan="1">XGBoost</td><td align="center" rowspan="1" colspan="1">N_estimators = 2000</td></tr><tr><td align="center" rowspan="1" colspan="1">Max_depth = 4</td></tr><tr><td align="center" rowspan="1" colspan="1">Min_child_weight = 2</td></tr><tr><td align="center" rowspan="1" colspan="1">Gamma = 0.9subsample = 0.8</td></tr><tr><td align="center" rowspan="1" colspan="1">Objective = &#x02018;binary:logistic&#x02019;</td></tr><tr><td align="center" rowspan="1" colspan="1">Scale_pos_weight = 1</td></tr><tr><td align="center" rowspan="6" colspan="1">Logistic Regression</td><td align="center" rowspan="1" colspan="1">N_jobs = 1</td></tr><tr><td align="center" rowspan="1" colspan="1">penalty = &#x02018;12&#x02019;</td></tr><tr><td align="center" rowspan="1" colspan="1">C = 1</td></tr><tr><td align="center" rowspan="1" colspan="1">fit_intercept = True</td></tr><tr><td align="center" rowspan="1" colspan="1">intercept_scaling = 1</td></tr><tr><td align="center" rowspan="1" colspan="1">max_iter = 100</td></tr></tbody></table></alternatives></table-wrap><p>EXtreme Gradient Boosting (XGB) is a boosting integrated learning algorithm that is a gradient lifting algorithm based on the CART regression tree. After multiple iterations, each iteration produces a weak classifier, and each classifier is trained based on the gradient of the previous classifier round. The basic idea can be understood as taking the second-order Taylor expansion of the loss function as its replacement function. The objective function of the algorithm is composed of the loss function L of the model and the regular term &#x003a9; to restrain the complexity of the model.</p><p>The four modeling algorithms mentioned above are built into a fusion model based on the voting mechanism, which is an integrated learning model following the principle of minority-majority, and reduces the variance through the integration of multiple models, thus improving the robustness of the model. Typically in the categorization case, the integrated learner <italic toggle="yes">h</italic><sub><italic toggle="yes">i</italic></sub><italic toggle="yes">(x)</italic> needs to predict a category token from the category labels, and in general, the frequently used method is the voting method (<xref rid="pone.0310410.e008" ref-type="disp-formula">Eq 2</xref>). If more than half of the votes are cast for a token, it is expected to be that token; otherwise, the prediction is rejected. Theoretically the final output is the most popular prediction in the base learner. The basic principle is shown in <xref rid="pone.0310410.g003" ref-type="fig">Fig 3</xref>.</p><disp-formula id="pone.0310410.e008">
<alternatives><graphic xlink:href="pone.0310410.e008.jpg" id="pone.0310410.e008g" position="anchor"/><mml:math id="M8" display="block" overflow="scroll"><mml:mi mathvariant="normal">H</mml:mi><mml:mo>(</mml:mo><mml:mi mathvariant="normal">x</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">c</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mrow><mml:msubsup><mml:mo stretchy="false">&#x02211;</mml:mo><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:msubsup><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">j</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msubsup><mml:mo>(</mml:mo><mml:mi mathvariant="normal">x</mml:mi><mml:mo>)</mml:mo><mml:mo>&#x0003e;</mml:mo><mml:mn>0.5</mml:mn><mml:mrow><mml:msubsup><mml:mo stretchy="false">&#x02211;</mml:mo><mml:mrow><mml:mi mathvariant="normal">k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">N</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mrow><mml:msubsup><mml:mo stretchy="false">&#x02211;</mml:mo><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:msubsup><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">j</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">k</mml:mi></mml:mrow></mml:msubsup><mml:mo>(</mml:mo><mml:mi mathvariant="normal">x</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">j</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></alternatives>
<label>(2)</label>
</disp-formula><fig position="float" id="pone.0310410.g003"><object-id pub-id-type="doi">10.1371/journal.pone.0310410.g003</object-id><label>Fig 3</label><caption><title>Schematic diagram of fusion model based on voting mechanism.</title></caption><graphic xlink:href="pone.0310410.g003" position="float"/></fig></sec><sec id="sec006"><title>2.4 Evaluation indicators</title><p>In artificial intelligence, the Confusion Matrix is a common visualization tool in supervised learning. Its main function is to summarize the results of a classifier. The common evaluation criteria used in evaluating the classification performance are: Accuracy, Precision, Recall, F1-score and the ROC curve (Eqs <xref rid="pone.0310410.e009" ref-type="disp-formula">3</xref>&#x02013;<xref rid="pone.0310410.e013" ref-type="disp-formula">7</xref>).</p><disp-formula id="pone.0310410.e009">
<alternatives><graphic xlink:href="pone.0310410.e009.jpg" id="pone.0310410.e009g" position="anchor"/><mml:math id="M9" display="block" overflow="scroll"><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">y</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">P</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">N</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">P</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">F</mml:mi><mml:mi mathvariant="normal">N</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">F</mml:mi><mml:mi mathvariant="normal">P</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">N</mml:mi></mml:mrow></mml:mfrac></mml:math></alternatives>
<label>(3)</label>
</disp-formula><disp-formula id="pone.0310410.e010">
<alternatives><graphic xlink:href="pone.0310410.e010.jpg" id="pone.0310410.e010g" position="anchor"/><mml:math id="M10" display="block" overflow="scroll"><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">P</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">F</mml:mi><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:mfrac></mml:math></alternatives>
<label>(4)</label>
</disp-formula><disp-formula id="pone.0310410.e011">
<alternatives><graphic xlink:href="pone.0310410.e011.jpg" id="pone.0310410.e011g" position="anchor"/><mml:math id="M11" display="block" overflow="scroll"><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">P</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">F</mml:mi><mml:mi mathvariant="normal">N</mml:mi></mml:mrow></mml:mfrac></mml:math></alternatives>
<label>(5)</label>
</disp-formula><disp-formula id="pone.0310410.e012">
<alternatives><graphic xlink:href="pone.0310410.e012.jpg" id="pone.0310410.e012g" position="anchor"/><mml:math id="M12" display="block" overflow="scroll"><mml:mi mathvariant="normal">F</mml:mi><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mo>*</mml:mo><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mo>*</mml:mo><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:mfrac></mml:math></alternatives>
<label>(6)</label>
</disp-formula><disp-formula id="pone.0310410.e013">
<alternatives><graphic xlink:href="pone.0310410.e013.jpg" id="pone.0310410.e013g" position="anchor"/><mml:math id="M13" display="block" overflow="scroll"><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">U</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo stretchy="false">&#x02211;</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>)</mml:mo><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></alternatives>
<label>(7)</label>
</disp-formula><p>Where TP refers to True Positive, TN refers to True Negative, FP refers to False Positive, and FN refers to False Negative; the Fl-score is a statistical measure of the precision of a dichotomous model, considering both the precision and the recall of the model. A higher F1 score indicates better performance of the model; AUC: The area under the curve is a numerical indicating how well the model will perform in different situations. In general, an AUC greater than 0.85 indicates excellent model performance; Learning Curve is a curve about the sample size of the training datasets, the average score on the training samples and cross-validation samples as well as between the score intervals. By observing the plotted Learning Curve graph, you gain a more intuitive understanding of the state of the model, such as: overfitting or underfitting.</p></sec></sec><sec id="sec007"><title>3 Result</title><sec id="sec008"><title>3.1 Demographic characterization</title><p>A total of 88,236 patients with confirmed IDC were included in this study from the SEER database, with 14 characteristic variables and outcome variables related to clinicopathology and patient demographics. Demographic variables included race, gender, marital status, and age, while clinicopathological variables included tumor size, estrogen status, progesterone status, HER2 status, TN staging, radiotherapy, and surgical treatment. All data distributions are shown in <xref rid="pone.0310410.t007" ref-type="table">Table 7</xref>. The number of positive and negative samples was equalized by undersampling M1 (3669): M0 (3669) = 1:1. The entire SEER dataset was divided into a training set (n = 5136, 70%) and a test set (n = 2202, 30%). Detailed distribution information is shown in <xref rid="pone.0310410.t008" ref-type="table">Table 8</xref>.</p><table-wrap position="float" id="pone.0310410.t007"><object-id pub-id-type="doi">10.1371/journal.pone.0310410.t007</object-id><label>Table 7</label><caption><title>Clinical and pathological characteristics of the study subjects.</title></caption><alternatives><graphic xlink:href="pone.0310410.t007" id="pone.0310410.t007g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">All</th><th align="center" rowspan="1" colspan="1">M1</th><th align="center" rowspan="1" colspan="1">M0</th></tr><tr><th align="center" rowspan="1" colspan="1">N = 88236</th><th align="center" rowspan="1" colspan="1">N = 3669</th><th align="center" rowspan="1" colspan="1">N = 84567</th></tr></thead><tbody><tr><td align="justify" rowspan="1" colspan="1">
<bold>Age</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c;50</td><td align="center" rowspan="1" colspan="1">19294 (21.9%)</td><td align="center" rowspan="1" colspan="1">914 (4.7%)</td><td align="center" rowspan="1" colspan="1">18380 (95.3%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e;50</td><td align="center" rowspan="1" colspan="1">68942 (78.1%)</td><td align="center" rowspan="1" colspan="1">2755 (3.9%)</td><td align="center" rowspan="1" colspan="1">66187 (96.0%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Sex</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Female</td><td align="center" rowspan="1" colspan="1">87458 (99.1%)</td><td align="center" rowspan="1" colspan="1">3621 (4.1%)</td><td align="center" rowspan="1" colspan="1">83837 (95.8%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Male</td><td align="center" rowspan="1" colspan="1">778 (0.8%)</td><td align="center" rowspan="1" colspan="1">48 (6.1%)</td><td align="center" rowspan="1" colspan="1">730 (93.8%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Race</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;White</td><td align="center" rowspan="1" colspan="1">68474 (77.6%)</td><td align="center" rowspan="1" colspan="1">2703 (3.9%)</td><td align="center" rowspan="1" colspan="1">65771 (96.0%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Black</td><td align="center" rowspan="1" colspan="1">9486 (10.7%)</td><td align="center" rowspan="1" colspan="1">581 (6.1%)</td><td align="center" rowspan="1" colspan="1">8905 (93.8%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;American Indian/Alaska Native</td><td align="center" rowspan="1" colspan="1">575 (0.6%)</td><td align="center" rowspan="1" colspan="1">24 (4.1%)</td><td align="center" rowspan="1" colspan="1">551 (95.8%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Asian or Pacific Islander</td><td align="center" rowspan="1" colspan="1">9701 (10.9%)</td><td align="center" rowspan="1" colspan="1">361 (3.7%)</td><td align="center" rowspan="1" colspan="1">9340 (96.2%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>ER Status Recode</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Negative</td><td align="center" rowspan="1" colspan="1">14662 (16.6%)</td><td align="center" rowspan="1" colspan="1">923 (6.2%)</td><td align="center" rowspan="1" colspan="1">13739 (93.7%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Positive</td><td align="center" rowspan="1" colspan="1">73574 (83.3%)</td><td align="center" rowspan="1" colspan="1">2746 (3.7%)</td><td align="center" rowspan="1" colspan="1">70828 (96.2%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>PR Status Recode</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Negative</td><td align="center" rowspan="1" colspan="1">23771 (26.9%)</td><td align="center" rowspan="1" colspan="1">1359 (5.8%)</td><td align="center" rowspan="1" colspan="1">22376 (94.1%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Positive</td><td align="center" rowspan="1" colspan="1">64465 (73.0%)</td><td align="center" rowspan="1" colspan="1">2274 (3.5%)</td><td align="center" rowspan="1" colspan="1">62191 (96.4%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>HER2 Recode</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Negative</td><td align="center" rowspan="1" colspan="1">75169 (85.1%)</td><td align="center" rowspan="1" colspan="1">2779 (3.6%)</td><td align="center" rowspan="1" colspan="1">72390 (96.3%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Positive</td><td align="center" rowspan="1" colspan="1">13067 (14.8%)</td><td align="center" rowspan="1" colspan="1">890 (6.8%)</td><td align="center" rowspan="1" colspan="1">12177 (93.1%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Marital status</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Single</td><td align="center" rowspan="1" colspan="1">14303 (16.4%)</td><td align="center" rowspan="1" colspan="1">13493 (94.3%)</td><td align="center" rowspan="1" colspan="1">810 (5.6%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Married</td><td align="center" rowspan="1" colspan="1">51439 (58.3%)</td><td align="center" rowspan="1" colspan="1">1768 (3.4%)</td><td align="center" rowspan="1" colspan="1">49671 (96.5%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Divorced</td><td align="center" rowspan="1" colspan="1">9740 (11.0%)</td><td align="center" rowspan="1" colspan="1">461 (4.7%)</td><td align="center" rowspan="1" colspan="1">9279 (95.2%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Unmarried or Domestic Partner</td><td align="center" rowspan="1" colspan="1">576 (0.7%)</td><td align="center" rowspan="1" colspan="1">550 (95.4%)</td><td align="center" rowspan="1" colspan="1">26 (4.5%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Widowed</td><td align="center" rowspan="1" colspan="1">11203 (12.6%)</td><td align="center" rowspan="1" colspan="1">545 (4.8%)</td><td align="center" rowspan="1" colspan="1">10658 (95.1%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Tumor Size(mm)</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c;100</td><td align="center" rowspan="1" colspan="1">87597 (99.3%)</td><td align="center" rowspan="1" colspan="1">3457 (3.9%)</td><td align="center" rowspan="1" colspan="1">84140 (96.0%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e;100</td><td align="center" rowspan="1" colspan="1">639 (0.7%)</td><td align="center" rowspan="1" colspan="1">212 (33.1%)</td><td align="center" rowspan="1" colspan="1">427 (66.8%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Chemotherapy recode</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="center" rowspan="1" colspan="1">34839 (39.4%)</td><td align="center" rowspan="1" colspan="1">2722 (7.8%)</td><td align="center" rowspan="1" colspan="1">32117 (92.1%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;None</td><td align="center" rowspan="1" colspan="1">53397 (60.5%)</td><td align="center" rowspan="1" colspan="1">947 (1.7%)</td><td align="center" rowspan="1" colspan="1">52450 (98.2%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Radiation recode</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="center" rowspan="1" colspan="1">50357 (57.1%)</td><td align="center" rowspan="1" colspan="1">1245 (2.4%)</td><td align="center" rowspan="1" colspan="1">49112 (97.5%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;None</td><td align="center" rowspan="1" colspan="1">37879 (42.9%)</td><td align="center" rowspan="1" colspan="1">2424 (6.3%)</td><td align="center" rowspan="1" colspan="1">35455 (93.6%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Surgery recode</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Surgery performed</td><td align="center" rowspan="1" colspan="1">83233 (94.3%)</td><td align="center" rowspan="1" colspan="1">1144 (1.3%)</td><td align="center" rowspan="1" colspan="1">82089 (98.6%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Not performed</td><td align="center" rowspan="1" colspan="1">5003 (5.6%)</td><td align="center" rowspan="1" colspan="1">2525 (50.4%)</td><td align="center" rowspan="1" colspan="1">2478 (49.5%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>T stage</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;T0</td><td align="center" rowspan="1" colspan="1">110 (0.1%)</td><td align="center" rowspan="1" colspan="1">30 (27.2%)</td><td align="center" rowspan="1" colspan="1">80 (72.7%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;T1</td><td align="center" rowspan="1" colspan="1">54376 (61.6%)</td><td align="center" rowspan="1" colspan="1">618 (1.1%)</td><td align="center" rowspan="1" colspan="1">53758 (98.8%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;T2</td><td align="center" rowspan="1" colspan="1">26813 (30.3%)</td><td align="center" rowspan="1" colspan="1">1361 (5.0%)</td><td align="center" rowspan="1" colspan="1">25452 (94.9%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;T3</td><td align="center" rowspan="1" colspan="1">4277 (4.8%)</td><td align="center" rowspan="1" colspan="1">648 (5.1%)</td><td align="center" rowspan="1" colspan="1">3629 (84.8%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;T4</td><td align="center" rowspan="1" colspan="1">2660 (3.0%)</td><td align="center" rowspan="1" colspan="1">1012 (38.0%)</td><td align="center" rowspan="1" colspan="1">1648 (61.9%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>N stage</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;N0</td><td align="center" rowspan="1" colspan="1">62875 (71.3%)</td><td align="center" rowspan="1" colspan="1">905 (1.4%)</td><td align="center" rowspan="1" colspan="1">61970 (98.5%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;N1</td><td align="center" rowspan="1" colspan="1">20359 (23.1%)</td><td align="center" rowspan="1" colspan="1">1688 (9.1%)</td><td align="center" rowspan="1" colspan="1">18493 (90.8%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;N2</td><td align="center" rowspan="1" colspan="1">2741 (3.1%)</td><td align="center" rowspan="1" colspan="1">307 (11.2%)</td><td align="center" rowspan="1" colspan="1">2434 (88.7%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;N3</td><td align="center" rowspan="1" colspan="1">2261 (2.6%)</td><td align="center" rowspan="1" colspan="1">591 (26.1%)</td><td align="center" rowspan="1" colspan="1">1670 (73.8%)</td></tr></tbody></table></alternatives></table-wrap><table-wrap position="float" id="pone.0310410.t008"><object-id pub-id-type="doi">10.1371/journal.pone.0310410.t008</object-id><label>Table 8</label><caption><title>Distribution of clinical pathological features in training and testing sets.</title></caption><alternatives><graphic xlink:href="pone.0310410.t008" id="pone.0310410.t008g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1">Variables</th><th align="center" colspan="2" rowspan="1">Training set (N = 5136)</th><th align="center" colspan="2" rowspan="1">Test set (N = 2202)</th></tr><tr><th align="center" rowspan="1" colspan="1">M0 (N = 2584)</th><th align="center" rowspan="1" colspan="1">M1 (N = 2552)</th><th align="center" rowspan="1" colspan="1">M0 (N = 1085)</th><th align="center" rowspan="1" colspan="1">M1 (N = 1117)</th></tr></thead><tbody><tr><td align="justify" rowspan="1" colspan="1">
<bold>Age</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c;50</td><td align="center" rowspan="1" colspan="1">573</td><td align="center" rowspan="1" colspan="1">643 (25.2%)</td><td align="center" rowspan="1" colspan="1">215 (19.8%)</td><td align="center" rowspan="1" colspan="1">217 (24.3%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e;50</td><td align="center" rowspan="1" colspan="1">2011</td><td align="center" rowspan="1" colspan="1">1909 (74.8%)</td><td align="center" rowspan="1" colspan="1">870 (80.2%)</td><td align="center" rowspan="1" colspan="1">846 (75.7%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Sex</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Male</td><td align="center" rowspan="1" colspan="1">22 (0.8%)</td><td align="center" rowspan="1" colspan="1">31 (1.2%)</td><td align="center" rowspan="1" colspan="1">5 (0.4%)</td><td align="center" rowspan="1" colspan="1">17 (1.5%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Female</td><td align="center" rowspan="1" colspan="1">2562 (99.1%)</td><td align="center" rowspan="1" colspan="1">2521 (98.7%)</td><td align="center" rowspan="1" colspan="1">1080 (99.5%)</td><td align="center" rowspan="1" colspan="1">1100 (98.4%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Race</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;White</td><td align="center" rowspan="1" colspan="1">1978 (76.5%)</td><td align="center" rowspan="1" colspan="1">410 (16.0%)</td><td align="center" rowspan="1" colspan="1">840 (77.4%)</td><td align="center" rowspan="1" colspan="1">828 (74.1%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Black</td><td align="center" rowspan="1" colspan="1">277 (10.7%)</td><td align="center" rowspan="1" colspan="1">1875 (73.4%)</td><td align="center" rowspan="1" colspan="1">130 (11.9%)</td><td align="center" rowspan="1" colspan="1">171 (15.3%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;American Indian/Alaska Native</td><td align="center" rowspan="1" colspan="1">24 (0.9%)</td><td align="center" rowspan="1" colspan="1">15 (0.6%)</td><td align="center" rowspan="1" colspan="1">4 (0.4%)</td><td align="center" rowspan="1" colspan="1">9 (10.8%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Asian or Pacific Islander</td><td align="center" rowspan="1" colspan="1">305 (11.8%)</td><td align="center" rowspan="1" colspan="1">252 (9.8%)</td><td align="center" rowspan="1" colspan="1">111 (10.2%)</td><td align="center" rowspan="1" colspan="1">109 (9.7%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>ER Status Recode</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="justify" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Negative</td><td align="center" rowspan="1" colspan="1">410 (15.8%)</td><td align="center" rowspan="1" colspan="1">655 (25.6%)</td><td align="center" rowspan="1" colspan="1">168 (15.4%)</td><td align="center" rowspan="1" colspan="1">268 (23.9%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Positive</td><td align="center" rowspan="1" colspan="1">2174 (84.1%)</td><td align="center" rowspan="1" colspan="1">1897 (74.3%)</td><td align="center" rowspan="1" colspan="1">917 (84.5%)</td><td align="center" rowspan="1" colspan="1">849 (76.0%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>PR Status Recode</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Negative</td><td align="center" rowspan="1" colspan="1">712 (27.5%)</td><td align="center" rowspan="1" colspan="1">975 (38.2%)</td><td align="center" rowspan="1" colspan="1">288 (26.5%)</td><td align="center" rowspan="1" colspan="1">420 (37.6%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Positive</td><td align="center" rowspan="1" colspan="1">1872 (72.4%)</td><td align="center" rowspan="1" colspan="1">1577 (61.7%)</td><td align="justify" rowspan="1" colspan="1">797 (73.4%)</td><td align="center" rowspan="1" colspan="1">697 (62.3%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>HER2 Recode</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Negative</td><td align="center" rowspan="1" colspan="1">2197 (85.0%)</td><td align="center" rowspan="1" colspan="1">1918 (75.1%)</td><td align="center" rowspan="1" colspan="1">941 (86.7%)</td><td align="center" rowspan="1" colspan="1">861 (77.0%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Positive</td><td align="center" rowspan="1" colspan="1">387 (14.9%)</td><td align="center" rowspan="1" colspan="1">634 (24.8%)</td><td align="center" rowspan="1" colspan="1">144 (13.2%)</td><td align="center" rowspan="1" colspan="1">256 (22.9%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Marital status</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Married</td><td align="center" rowspan="1" colspan="1">1522 (58.9%)</td><td align="center" rowspan="1" colspan="1">1239 (48.6%)</td><td align="center" rowspan="1" colspan="1">624 (57.5%)</td><td align="center" rowspan="1" colspan="1">529 (47.4%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Single</td><td align="center" rowspan="1" colspan="1">400 (15.4%)</td><td align="center" rowspan="1" colspan="1">557 (21.8%)</td><td align="center" rowspan="1" colspan="1">165 (15.2%)</td><td align="center" rowspan="1" colspan="1">253 (22.6%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Divorced</td><td align="center" rowspan="1" colspan="1">271 (10.4%)</td><td align="center" rowspan="1" colspan="1">325 (12.7%)</td><td align="center" rowspan="1" colspan="1">123 (11.3%)</td><td align="center" rowspan="1" colspan="1">136 (12.1%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Unmarried or Domestic Partner</td><td align="justify" rowspan="1" colspan="1">20 (0.8%)</td><td align="center" rowspan="1" colspan="1">18 (0.7%)</td><td align="center" rowspan="1" colspan="1">5 (0.5%)</td><td align="center" rowspan="1" colspan="1">8 (0.7%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Widowed</td><td align="center" rowspan="1" colspan="1">331 (12.8%)</td><td align="center" rowspan="1" colspan="1">369 (14.4%)</td><td align="center" rowspan="1" colspan="1">154 (14.1%)</td><td align="center" rowspan="1" colspan="1">176 (15.7%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Separated</td><td align="center" rowspan="1" colspan="1">40 (1.5%)</td><td align="center" rowspan="1" colspan="1">44 (1.7%)</td><td align="center" rowspan="1" colspan="1">14 (1.2%)</td><td align="center" rowspan="1" colspan="1">15 (1.3%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Tumor Size(mm)</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c;100</td><td align="center" rowspan="1" colspan="1">2571 (99.5%)</td><td align="center" rowspan="1" colspan="1">2403 (94.2%)</td><td align="center" rowspan="1" colspan="1">1083 (99.8%)</td><td align="center" rowspan="1" colspan="1">1052 (94.2%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e;100</td><td align="center" rowspan="1" colspan="1">13 (0.5%)</td><td align="center" rowspan="1" colspan="1">149 (5.8%)</td><td align="center" rowspan="1" colspan="1">2 (0.2%)</td><td align="center" rowspan="1" colspan="1">65 (5.8%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Chemotherapy recode</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;None</td><td align="center" rowspan="1" colspan="1">1594 (61.6%)</td><td align="center" rowspan="1" colspan="1">656 (25.7%)</td><td align="center" rowspan="1" colspan="1">393 (36.2%)</td><td align="center" rowspan="1" colspan="1">291 (26.0%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="center" rowspan="1" colspan="1">990 (38.3%)</td><td align="center" rowspan="1" colspan="1">1898 (74.2%)</td><td align="center" rowspan="1" colspan="1">692 (63.7%)</td><td align="center" rowspan="1" colspan="1">826 (73.9%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Radiation recode</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;None</td><td align="center" rowspan="1" colspan="1">1097 (42.5%)</td><td align="center" rowspan="1" colspan="1">1702 (66.7%)</td><td align="center" rowspan="1" colspan="1">481 (44.3%)</td><td align="center" rowspan="1" colspan="1">722 (64.6%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="center" rowspan="1" colspan="1">1487 (57.5%)</td><td align="center" rowspan="1" colspan="1">850 (33.3%)</td><td align="center" rowspan="1" colspan="1">604 (55.7%)</td><td align="center" rowspan="1" colspan="1">395 (35.4%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Surgery recode</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;None</td><td align="center" rowspan="1" colspan="1">79 (3.1%)</td><td align="center" rowspan="1" colspan="1">1739 (68.1%)</td><td align="center" rowspan="1" colspan="1">41 (3.8%)</td><td align="center" rowspan="1" colspan="1">786 (70.4%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="center" rowspan="1" colspan="1">2505 (96.9%)</td><td align="center" rowspan="1" colspan="1">813 (31.8%)</td><td align="center" rowspan="1" colspan="1">1044 (96.2%)</td><td align="center" rowspan="1" colspan="1">331 (29.6%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>T stage</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;T0</td><td align="center" rowspan="1" colspan="1">1 (&#x0003c;0.1%)</td><td align="center" rowspan="1" colspan="1">17 (0.6%)</td><td align="center" rowspan="1" colspan="1">1 (&#x0003c;0.1%)</td><td align="center" rowspan="1" colspan="1">13 (1.1%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;T1</td><td align="center" rowspan="1" colspan="1">1628 (63.0%)</td><td align="center" rowspan="1" colspan="1">434 (17.0%)</td><td align="center" rowspan="1" colspan="1">703 (64.8%)</td><td align="center" rowspan="1" colspan="1">184 (16.5%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;T2</td><td align="center" rowspan="1" colspan="1">779 (30.1%)</td><td align="center" rowspan="1" colspan="1">940 (36.8%)</td><td align="center" rowspan="1" colspan="1">313 (28.8%)</td><td align="center" rowspan="1" colspan="1">421 (37.6%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;T3</td><td align="center" rowspan="1" colspan="1">113 (4.4%)</td><td align="center" rowspan="1" colspan="1">451 (17.6%)</td><td align="center" rowspan="1" colspan="1">43 (3.9%)</td><td align="center" rowspan="1" colspan="1">197 (17.6%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;T4</td><td align="center" rowspan="1" colspan="1">63 (2.4%)</td><td align="center" rowspan="1" colspan="1">710 (27.8%)</td><td align="center" rowspan="1" colspan="1">25 (2.3%)</td><td align="center" rowspan="1" colspan="1">302 (27.0%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>N stage</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;N0</td><td align="center" rowspan="1" colspan="1">1916 (74.1%)</td><td align="center" rowspan="1" colspan="1">628 (24.6%)</td><td align="center" rowspan="1" colspan="1">813 (74.9%)</td><td align="center" rowspan="1" colspan="1">277 (24.8%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;N1</td><td align="center" rowspan="1" colspan="1">546 (21.1%)</td><td align="center" rowspan="1" colspan="1">1291 (50.6%)</td><td align="center" rowspan="1" colspan="1">225 (20.7%)</td><td align="center" rowspan="1" colspan="1">575 (51.5%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;N2</td><td align="center" rowspan="1" colspan="1">73 (2.8%)</td><td align="center" rowspan="1" colspan="1">220 (18.6%)</td><td align="center" rowspan="1" colspan="1">24 (2.2%)</td><td align="center" rowspan="1" colspan="1">87 (7.8%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;N3</td><td align="center" rowspan="1" colspan="1">49 (1.9%)</td><td align="center" rowspan="1" colspan="1">413 (16.2%)</td><td align="center" rowspan="1" colspan="1">23 (2.1%)</td><td align="center" rowspan="1" colspan="1">178 (15.9%)</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec009"><title>3.2 One-way logistic regression analysis</title><p>Univariate chi-square test analysis showed (<xref rid="pone.0310410.t009" ref-type="table">Table 9</xref>) that age, gender, race, ER/PR/HER2 status, marital status, tumor size, radiological and surgical treatments, and TN staging in IDC patients were significantly associated with the outcome variable M (P&#x0003c;0.05). Additionally, one-way logistic regression analysis of the significantly different variables showed that HER2 status, tumor size, radiotherapy, chemotherapy, surgical treatment, and TN staging may be risk factors for the development of cancer metastasis in patients with IDC. These six variables were used for further machine learning modeling studies.</p><table-wrap position="float" id="pone.0310410.t009"><object-id pub-id-type="doi">10.1371/journal.pone.0310410.t009</object-id><label>Table 9</label><caption><title>Univariate and multivariate logistic regression analysis.</title></caption><alternatives><graphic xlink:href="pone.0310410.t009" id="pone.0310410.t009g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1">Variables</th><th align="center" colspan="2" rowspan="1">Univariate analysis</th><th align="center" colspan="2" rowspan="1">Multivariate logistic regression analysis</th></tr><tr><th align="center" rowspan="1" colspan="1">Chi-Square</th><th align="center" rowspan="1" colspan="1">P-value</th><th align="center" rowspan="1" colspan="1">OR (95%CI)</th><th align="center" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="justify" rowspan="1" colspan="1">
<bold>Age</bold>
</td><td align="center" rowspan="1" colspan="1">125.398</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c;50</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e;50</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.031 (0.865&#x02013;1.229)</td><td align="center" rowspan="1" colspan="1">0.743</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Sex</bold>
</td><td align="center" rowspan="1" colspan="1">5.941</td><td align="center" rowspan="1" colspan="1">0.015</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Male</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Female</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.802 (0.947&#x02013;3.429)</td><td align="center" rowspan="1" colspan="1">0.073</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Race</bold>
</td><td align="center" rowspan="1" colspan="1">37.240</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;White</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Black</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.285 (0.558&#x02013;2.962)</td><td align="center" rowspan="1" colspan="1">0.556</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;American Indian/Alaska Native</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.153 (0.504&#x02013;2.639)</td><td align="center" rowspan="1" colspan="1">0.736</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Asian or Pacific Islander</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.560 (0.695&#x02013;3.501)</td><td align="center" rowspan="1" colspan="1">0.281</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>ER Status Recode</bold>
</td><td align="center" rowspan="1" colspan="1">99.689</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Negative</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Positive</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.943 (0.744&#x02013;1.195)</td><td align="center" rowspan="1" colspan="1">0.627</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>PR Status Recode</bold>
</td><td align="center" rowspan="1" colspan="1">96.711</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Negative</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Positive</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.178 (0.956&#x02013;1.451)</td><td align="center" rowspan="1" colspan="1">0.123</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>HER2 Recode</bold>
</td><td align="center" rowspan="1" colspan="1">112.479</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Negative</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Positive</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.205 (1.000&#x02013;1.451)</td><td align="center" rowspan="1" colspan="1">0.050</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Marital status</bold>
</td><td align="center" rowspan="1" colspan="1">89.147</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Married</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Single</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.851 (0.672&#x02013;1.078)</td><td align="center" rowspan="1" colspan="1">0.182</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Divorced</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.868 (0.454&#x02013;1.660)</td><td align="center" rowspan="1" colspan="1">0.669</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Unmarried or Domestic Partner</td><td align="justify" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.993 (0.755&#x02013;1.306)</td><td align="center" rowspan="1" colspan="1">0.959</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Separated</td><td align="justify" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.899 (0.667&#x02013;1.212)</td><td align="center" rowspan="1" colspan="1">0.484</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Widowed</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.910 (0.317&#x02013;2.087)</td><td align="center" rowspan="1" colspan="1">0.825</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Tumor Size(mm)</bold>
</td><td align="center" rowspan="1" colspan="1">2186.407</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c;100</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e;100</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2.513 (1.360&#x02013;4.644)</td><td align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Chemotherapy recode</bold>
</td><td align="center" rowspan="1" colspan="1">991.334</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;None</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2.343 (1.960&#x02013;2.799)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Radiation recode</bold>
</td><td align="center" rowspan="1" colspan="1">393.383</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;None</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.635 (0.546&#x02013;0.740)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Surgery recode</bold>
</td><td align="center" rowspan="1" colspan="1">3419.256</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;None</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.027 (0.022&#x02013;0.033)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>T stage</bold>
</td><td align="center" rowspan="1" colspan="1">2126.272</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;T0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;T1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.155 (0.031&#x02013;0.785)</td><td align="center" rowspan="1" colspan="1">0.897</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;T2</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.277 (0.055&#x02013;1.401)</td><td align="center" rowspan="1" colspan="1">0.430</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;T3</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.518 (0.101&#x02013;2.652)</td><td align="center" rowspan="1" colspan="1">0.121</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;T4</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.115 (0.217&#x02013;5.736)</td><td align="center" rowspan="1" colspan="1">0.024</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>N stage</bold>
</td><td align="center" rowspan="1" colspan="1">1885.641</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;N0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;N1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2.419 (2.039&#x02013;2.871)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;N2</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4.238 (3.105&#x02013;5.783)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;N3</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">8.785 (6.424&#x02013;12.015) (6.424&#x02013;12.015)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec010"><title>3.3 Correlation analysis of characteristic variables</title><p>The correlation analysis of the feature variables of the datasets demonstrates information about the degree of interaction among these variables. This study uses heat maps to show the correlation of these features with the predictions of the ML algorithm. In the heat map, color indicates the degree of correlation, the darker the color the higher the correlation between the parameters. <xref rid="pone.0310410.g004" ref-type="fig">Fig 4</xref> shows the correlation matrix of 13 variables in the datasets, displaying the correlation between variables. Each cell in the matrix shows the Spearman correlation coefficient between two variables. From the graph, it can be seen that there is a significant negative correlation between chemotherapy and TN staging, while T staging is significantly positively correlated with tumor size. In clinical practice, the definition of T staging is based on the diameter of the tumor. This is consistent with clinical experience.</p><fig position="float" id="pone.0310410.g004"><object-id pub-id-type="doi">10.1371/journal.pone.0310410.g004</object-id><label>Fig 4</label><caption><title>Heat map of the correlation of features.</title></caption><graphic xlink:href="pone.0310410.g004" position="float"/></fig></sec><sec id="sec011"><title>3.4 Model performance evaluation</title><p>The performance of six machine models was built and compared based on the confusion matrix, learning curves, receiver operating characteristic curves (ROCs), ten-fold cross-validation accuracy, precision, recall, F1-score and AUC value. The results are shown in Figs <xref rid="pone.0310410.g005" ref-type="fig">5</xref>&#x02013;<xref rid="pone.0310410.g008" ref-type="fig">8</xref>. Each model has its relative advantages. Taken together, the fusion model has higher indicators, with accuracy, Recall, Precision, F1-score, and AUC values of 0.867, 0.805, 0.929, 0.856, and 0.94, respectively. One of the biggest drawbacks of the fusion model based on voting mechanism is that if our fusion algorithms are all carefully tuned algorithms, the voting scheme may lead to overfitting. The assessment of the model state was performed using learning curves, and after cross-validation, the fitting effect of RF and SVM is very unsatisfactory. The LR model is the best. Although FM is not the best, it has already reached a relatively ideal state.</p><fig position="float" id="pone.0310410.g005"><object-id pub-id-type="doi">10.1371/journal.pone.0310410.g005</object-id><label>Fig 5</label><caption><title>The confusion matrix of the models in the test set.</title></caption><graphic xlink:href="pone.0310410.g005" position="float"/></fig><fig position="float" id="pone.0310410.g006"><object-id pub-id-type="doi">10.1371/journal.pone.0310410.g006</object-id><label>Fig 6</label><caption><title>Comparison of Ten-fold Cross validation metrics for various machine learning models.</title></caption><graphic xlink:href="pone.0310410.g006" position="float"/></fig><fig position="float" id="pone.0310410.g007"><object-id pub-id-type="doi">10.1371/journal.pone.0310410.g007</object-id><label>Fig 7</label><caption><title>Box plot comparing the average and standard deviation of indicators.</title></caption><graphic xlink:href="pone.0310410.g007" position="float"/></fig><fig position="float" id="pone.0310410.g008"><object-id pub-id-type="doi">10.1371/journal.pone.0310410.g008</object-id><label>Fig 8</label><caption><title>The learning curve of each machine learning prediction model.</title></caption><graphic xlink:href="pone.0310410.g008" position="float"/></fig></sec><sec id="sec012"><title>3.5 Importance analysis of characteristic variables</title><p>The PermutationImportance method provided by eli5 in Python is used to calculate the importance of features. <xref rid="pone.0310410.g009" ref-type="fig">Fig 9</xref> shows the feature importance ranking of the five prediction models for cancer metastasis prediction for the 13 feature variables after dimensionality reduction processing on the training set. Variables screened by univariate and multivariate logistic analyses contributed to the predictions in all five models. Surgery ranked first or second in terms of feature importance among all predictive models, indicating that surgery has a strong impact on the prediction of cancer metastasis in IDC. Variables such as age, gender, and marital status always rank in the bottom five, and there is no significant difference in their contribution to the model.</p><fig position="float" id="pone.0310410.g009"><object-id pub-id-type="doi">10.1371/journal.pone.0310410.g009</object-id><label>Fig 9</label><caption><title>Contributions of the clinical features variables to risk prediction using feature importance.</title></caption><graphic xlink:href="pone.0310410.g009" position="float"/></fig></sec></sec><sec sec-type="conclusions" id="sec013"><title>4 Discussion</title><p>Over the past few decades, the incidence of death in patients with BC has decreased significantly due to advances in surgical methods and systematic neoadjuvant chemotherapy [<xref rid="pone.0310410.ref030" ref-type="bibr">30</xref>]. Metastatic BC, rather than primary tumors, causes more than 90% of cancer-related deaths [<xref rid="pone.0310410.ref031" ref-type="bibr">31</xref>]. As there are no significant symptoms in the early stage of BC, it is easy to be ignored by patients. As a result, the disease has often developed to the middle and late stages when it is found, and recurrence and metastasis are easy to occur after systematic treatment, which is not only difficult to treat, but also greatly affects the quality of life of the patients. In the current treatment process, pathological examination is the gold standard for metastatic tumors. When a physician suspects that a patient has metastatic cancer somewhere, they usually first have the patient undergo a series of immunohistochemical tests to aid in the diagnosis; not only will this invasive test be more physically harmful to the patient, but the pathology results are usually available 2 to 3 days after the test. This waiting time is critical to improving the survival chances of patients with advanced hematogenous metastatic BC [<xref rid="pone.0310410.ref032" ref-type="bibr">32</xref>]. Therefore, early identification of patients with IDC at risk of developing distant metastases from cancer is extremely important. With the rapid advancements in computer technology and artificial intelligence, it has become a trend to use machine learning to analyze patient data to help doctors make correct judgments [<xref rid="pone.0310410.ref033" ref-type="bibr">33</xref>]. Currently, related scholars have achieved promising results in the prediction of survival rate and survival status of cancer patients using machine learning methods such as random forest, SVM, and neural network [<xref rid="pone.0310410.ref034" ref-type="bibr">34</xref>, <xref rid="pone.0310410.ref035" ref-type="bibr">35</xref>].</p><p>This study uses only clinical and pathological indicators of patients with IDC obtained based on the SEER database to establish a validated prediction model. This model aims to classify and predict whether a patient has cancer metastasis, which can easily predict the risk of organ metastasis without imaging or any laboratory tests. This model can help clinicians make a rapid and reliable diagnosis and improve their work efficiency, and can develop individualized treatment plans for different individuals [<xref rid="pone.0310410.ref036" ref-type="bibr">36</xref>], saving treatment time for patients by identifying the risk of metastasis early, thus reducing mortality.</p><p>This study builds a prediction model based on four algorithms: logistic regression, SVM, random forest, and XGBoost. From the results after ten-fold cross-validation, each prediction model has its own advantages and disadvantages. The accuracy and AUC of the XGBoost model predictions are relatively high, which indicates a high degree of overall prediction accuracy, along with the high ability of this classifier to rank samples. However, the precision, recall and F1 value of this model are low, which indicates its low prediction accuracy in positive sample results, and a potential for underdiagnosis. Conversely, the LR and RF models have low metrics and are not suitable as good classifiers for risk prediction. The performance of the fusion model based on the voting mechanism on all the indicators is improved to a certain extent compared to the individual base models. High accuracy indicates that the model can classify patients more accurately, high sensitivity implies a low rate of missed diagnosis, and low error indicates stable predictive performance of the model. In addition, learning curves were used to diagnose the overfitting behavior of the model. As the number of training samples increased, the accuracy gap between RF on the training and cross-validation sets was large, indicating that the models can fit the known data well, but the generalization ability is very poor, which is an overfitting. The learning curves of other models can converge on both the training and validation sets, but SVM is only 0.75, with a slight deviation and unsatisfactory fitting. At this time, FM convergence value was approaching 0.9, indicating that the algorithm itself has good fitting ability, the model&#x02019;s generalization ability is also very strong, and the fitting effect is price ideal. Therefore, the Fusion classifier is more suitable as a good predictive model to predict the risk of IDC distant organ transfer. This study is innovative in using ML algorithms to predict the risk of cancer metastasis in patients with IDC. Currently, a number of academics and researchers in the medical field have used traditional linear statistical models and a single machine learning model to predict the risk of BM in patients with IDC [<xref rid="pone.0310410.ref037" ref-type="bibr">37</xref>&#x02013;<xref rid="pone.0310410.ref039" ref-type="bibr">39</xref>], but few studies have used multi-model fusion techniques for modeling and prediction. In this study, a fusion machine learning model based on multiple algorithms was developed, which was able to more accurately predict the risk of cancer metastasis in patients with IDC and outperformed other single machine learning models developed in this study.</p><p>The ranking importance principle was used to analyze the relative characteristic importance of the variables in each ML model [<xref rid="pone.0310410.ref040" ref-type="bibr">40</xref>]. We found that although the relative feature importance varied slightly across ML models, Surgery, T, N staging, and Tumor Size were the top-ranked variables in most of the models, in contrast to the age, race and ER Status variables, which was the last-ranked variable in most of the models, but also contributed to the models. In this study, five variables, Surgery, T and N staging, Tumor Size, Chemotherapy record, were strong predictors of the risk of distant metastasis of IDC with good predictive value. This suggests that for which variables were crucial for the creation of the predictive model in this experiment, these characterizing variables could be considered for inclusion in the study when conducting such experiments in the future, to inform the selection of variables in the database.</p><p>In the field of medicine, many researchers have attempted to identify independent risk factors that influence the development of cancer metastasis in patients with IDC. In this study, we analyzed the pathological characteristic variables of the patients&#x02019; based on one-way logistic regression and delved into the risk factors affecting the development of cancer metastasis in the patients. We identified that HER2 status, tumor size, radiotherapy, chemotherapy, surgical treatment, and TN staging are risk factors for cancer metastasis in IDC. In clinical practice, patients with low and positive HER2 expression generally have higher tumor grades, larger tumors, more lymph node metastases [<xref rid="pone.0310410.ref041" ref-type="bibr">41</xref>], a smaller percentage of lobular carcinomas [<xref rid="pone.0310410.ref042" ref-type="bibr">42</xref>], and an increased risk of brain metastases [<xref rid="pone.0310410.ref043" ref-type="bibr">43</xref>]. Qi et al. obtained a higher risk of metastasis in HER2-positive patients than in HER2-negative patients in their analysis of risk factors for developing internal breast lymph node metastasis in BC [<xref rid="pone.0310410.ref044" ref-type="bibr">44</xref>], which is consistent with the results of our study. Tumor size was positively correlated with the odds of developing breast tumors. Yazdani et al. found that tumor size was a risk factor for developing bone metastases in BC, and the larger the tumor, the greater the likelihood of bone metastases [<xref rid="pone.0310410.ref045" ref-type="bibr">45</xref>]. In clinical practice, T stage means the size and extent of the primary tumor. In our results, patients with tumor diameters greater than 100 mm and T4 stage were more likely to develop metastasis of cancer cells, which is also consistent with the results of related studies and clinical experience. Poortmans et al [<xref rid="pone.0310410.ref046" ref-type="bibr">46</xref>] reported a lower rate of lymph node metastasis (&#x0003c;1.5%) in patients with BC receiving systemic therapy. In our results, patients receiving systemic therapy were less likely to develop cancer metastasis. The results of this study provide a theoretical basis for clinicians to assess the prognosis of patients with IDC, which can be used by physicians to develop more precise and individualized treatment plans for their patients.</p><p>However, few studies have focused on combining machine learning to predict the risk of distant metastasis of cancer cells in IDC. Therefore, in this study, we built a model with good predictive performance and good ability to fit the data for predicting the risk of cancer metastasis in IDC patients, based on data from the SEER database and incorporating four machine learning models. Our predictive model allows clinicians to easily input relevant clinical and pathological indicators of their patients into the model, which will calculate the patient&#x02019;s risk of cancer metastasis and then make quick and accurate personalized decisions for their patients based on the predictive output, and can be used as the basis for clinicians to explain their decisions to patients and engage them in their treatment choices. However, our study has certain limitations. Firstly, the data used in this study were limited by the region, quantity, and subjectivity of the feature selection, which limited the final experimental results. Secondly, when artificial intelligence is integrated into the interpretation by clinical physicians, there may be diverse manifestations in clinical practice [<xref rid="pone.0310410.ref047" ref-type="bibr">47</xref>]. Moreover, this was a retrospective study that needs to be validated through prospective research.</p></sec><sec sec-type="conclusions" id="sec014"><title>5 Conclusion</title><p>In this study, we constructed an advanced prediction model that integrates four algorithms: random forest, logistic regression, SVM, and XGB, based on a voting mechanism. This risk prediction model has superior predictive performance and high medical application value. The integrated model based on the voting mechanism shows further improvement upon the already effective predictions of individual models. This enhancement contributes to the improved ability of physicians to accurately identify malignant tumors in breast cancer, holding practical significance for timely and effective treatment for breast cancer patients.</p></sec><sec id="sec015" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pone.0310410.s001" position="float" content-type="local-data"><label>S1 Data</label><caption><p>(ZIP)</p></caption><media xlink:href="pone.0310410.s001.zip"/></supplementary-material></sec></body><back><ack><p>The authors would like to thank all the reviewers who participated in the review. We would like to express deep sense of appreciation and heartfelt thanks the public database provided by the National Cancer Institute, American, for providing data support for this study. We would like to thank Editage (<ext-link xlink:href="http://www.editage.cn/" ext-link-type="uri">www.editage.cn</ext-link>) for English language editing.</p></ack><ref-list><title>References</title><ref id="pone.0310410.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>L</given-names></name>, <name><surname>Tian</surname><given-names>H</given-names></name>, <name><surname>Zhang</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Prediction for distant metastasis of breast cancer using dynamic contrast-enhanced magnetic resonance imaging images under deep learning[J]</article-title>. <source>Computational Intelligence and Neuroscience</source>, <year>2022</year>: <fpage>6126061</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1155/2022/6126061</pub-id><pub-id pub-id-type="pmid">35720877</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Balaha</surname><given-names>HM</given-names></name>, <name><surname>Antar</surname><given-names>ER</given-names></name>, <name><surname>Saafan</surname><given-names>MM</given-names></name>, <etal>et al</etal>. <article-title>A comprehensive framework towards segmenting and classifying breast cancer patients using deep learning and Aquila optimizer[J]</article-title>. <source>Journal of Ambient Intelligence and Humanized Computing</source>, <year>2023</year>, <volume>14</volume>(<issue>6</issue>): <fpage>7897</fpage>&#x02013;<lpage>7917</lpage>.</mixed-citation></ref><ref id="pone.0310410.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Sung</surname><given-names>H</given-names></name>, <name><surname>Ferlay</surname><given-names>J</given-names></name>, <name><surname>Siegel</surname><given-names>RL</given-names></name>, <etal>et al</etal>. <article-title>Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]</article-title>. <source>CA Cancer J Clin</source>, <volume>2021</volume>, <volume>71</volume>(<issue>3</issue>): <fpage>209</fpage>&#x02013;<lpage>249</lpage>.</mixed-citation></ref><ref id="pone.0310410.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Bray</surname><given-names>F</given-names></name>, <name><surname>Ferlay</surname><given-names>J</given-names></name>, <name><surname>Soerjomataram</surname><given-names>I</given-names></name>, <etal>et al</etal>. <article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]</article-title>. <source>CA: a cancer journal for clinicians</source>, <year>2018</year>, <volume>68</volume>(<issue>6</issue>): <fpage>394</fpage>&#x02013;<lpage>424</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3322/caac.21492</pub-id><pub-id pub-id-type="pmid">30207593</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Baghdadi</surname><given-names>NA</given-names></name>, <name><surname>Malki</surname><given-names>A</given-names></name>, <name><surname>Balaha</surname><given-names>HM</given-names></name>, <etal>et al</etal>. <article-title>Classification of breast cancer using a manta-ray foraging optimized transfer learning framework[J]</article-title>. <source>PeerJ Computer Science</source>, <year>2022</year>, <volume>8</volume>: <fpage>e1054</fpage>.</mixed-citation></ref><ref id="pone.0310410.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>B&#x000f6;ger</surname><given-names>C</given-names></name>, <name><surname>Behrens</surname><given-names>HM</given-names></name>, <name><surname>R&#x000f6;cken</surname><given-names>C</given-names></name>. <article-title>Ki67&#x02014;An unsuitable marker of gastric cancer prognosis unmasks intratumoral heterogeneity[J]</article-title>. <source>J Surg Oncol</source>, <year>2016</year>, <volume>113</volume>(<issue>1</issue>): <fpage>46</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">26709194</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>La Vecchia</surname><given-names>C</given-names></name>, <name><surname>Bosetti</surname><given-names>C</given-names></name>, <name><surname>Lucchini</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Cancer mortality in Europe, 2000&#x02013;2004 and an overview of trends since 1975[J]</article-title>. <source>Ann Oncol</source>, <year>2010</year>, <volume>21</volume>(<issue>6</issue>): <fpage>1323</fpage>&#x02013;<lpage>1360</lpage>.<pub-id pub-id-type="pmid">19948741</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>W</given-names></name>, <name><surname>Zhang</surname><given-names>R</given-names></name>, <name><surname>Ling</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Automatic recognition of breast invasive ductal carcinoma based on terahertz spectroscopy with wavelet packet transform and machine learning[J]</article-title>. <source>Biomedical optics express</source>, <year>2020</year>, <volume>11</volume>(<issue>2</issue>): <fpage>971</fpage>&#x02013;<lpage>981</lpage>.<pub-id pub-id-type="pmid">32206399</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Ma</surname><given-names>W</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Xu</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Distant metastasis prediction via a multi-feature fusion model in breast cancer[J]</article-title>. <source>Aging (Albany NY)</source>, <year>2020</year>, <volume>12</volume>(<issue>18</issue>): <fpage>18151</fpage>.<pub-id pub-id-type="pmid">32989175</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Dheeba</surname><given-names>J</given-names></name>, <name><surname>Singh</surname><given-names>NA</given-names></name>, <name><surname>Selvi</surname><given-names>ST</given-names></name>. <article-title>Computer-aided detection of breast cancer on mammograms: A swarm intelligence optimized wavelet neural network approach[J]</article-title>. <source>Journal of biomedical informatics</source>, <year>2014</year>, <volume>49</volume>: <fpage>45</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">24509074</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Naji</surname><given-names>MA</given-names></name>, <name><surname>El Filali</surname><given-names>S</given-names></name>, <name><surname>Aarika</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Machine learning algorithms for breast cancer prediction and diagnosis[J]</article-title>. <source>Procedia Computer Science</source>, <year>2021</year>, <volume>191</volume>: <fpage>487</fpage>&#x02013;<lpage>492</lpage>.</mixed-citation></ref><ref id="pone.0310410.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>RY</given-names></name>, <name><surname>Coyner</surname><given-names>AS</given-names></name>, <name><surname>Kalpathy-Cramer</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Introduction to Machine Learning, Neural Networks, and Deep Learning[J]</article-title>. <source>Transl Vis Sci Technol</source>, <year>2020</year>, <volume>9</volume>(<issue>2</issue>): <fpage>14</fpage>&#x02013;<lpage>15</lpage>.</mixed-citation></ref><ref id="pone.0310410.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Battineni</surname><given-names>G</given-names></name>, <name><surname>Chintalapudi</surname><given-names>N</given-names></name>, <name><surname>Amenta</surname><given-names>F</given-names></name>. <article-title>Performance analysis of different machine learning algorithms in breast cancer predictions[J]</article-title>. <source>EAI Endorsed Transactions on Pervasive Health and Technology</source>, <year>2020</year>, <volume>6</volume>(<issue>23</issue>).</mixed-citation></ref><ref id="pone.0310410.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Zhou</surname><given-names>Z</given-names></name>, <name><surname>Dong</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Predicting breast cancer 5-year survival using machine learning: A systematic review[J]</article-title>. <source>PloS one</source>, <year>2021</year>, <volume>16</volume>(<issue>4</issue>): <fpage>e0250370</fpage>.<pub-id pub-id-type="pmid">33861809</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Ahmad</surname><given-names>S</given-names></name>, <name><surname>Ullah</surname><given-names>T</given-names></name>, <name><surname>Ahmad</surname><given-names>I</given-names></name>, <etal>et al</etal>. <article-title>A novel hybrid deep learning model for metastatic cancer detection[J]</article-title>. <source>Computational Intelligence and Neuroscience</source>, <year>2022</year>, <volume>2022</volume>(<issue>1</issue>): <fpage>8141530</fpage>.<pub-id pub-id-type="pmid">35785076</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Islam M</surname><given-names>M</given-names></name>, <name><surname>Haque M</surname><given-names>R</given-names></name>, <name><surname>Iqbal</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Breast cancer prediction: a comparative study using machine learning techniques[J]</article-title>. <source>SN Computer Science</source>, <year>2020</year>, <volume>1</volume>: <fpage>1</fpage>&#x02013;<lpage>14</lpage>.</mixed-citation></ref><ref id="pone.0310410.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Choudhury</surname><given-names>A.</given-names></name>
<article-title>Predicting cancer using supervised machine learning: Mesothelioma[J]</article-title>. <source>Technology and Health Care</source>, <year>2021</year>, <volume>29</volume>(<issue>1</issue>): <fpage>45</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">32568137</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Alfian</surname><given-names>G</given-names></name>, <name><surname>Syafrudin</surname><given-names>M</given-names></name>, <name><surname>Fahrurrozi</surname><given-names>I</given-names></name>, <etal>et al</etal>. <article-title>Predicting breast cancer from risk factors using SVM and extra-trees-based feature selection method[J]</article-title>. <source>Computers</source>, <year>2022</year>, <volume>11</volume>(<issue>9</issue>): <fpage>136</fpage>&#x02013;<lpage>137</lpage>.</mixed-citation></ref><ref id="pone.0310410.ref019"><label>19</label><mixed-citation publication-type="book"><name><surname>Afolayan</surname><given-names>JO</given-names></name>, <name><surname>Adebiyi</surname><given-names>MO</given-names></name>, <name><surname>Arowolo</surname><given-names>MO</given-names></name>, <etal>et al</etal>. <source>Breast cancer detection using particle swarm optimization and decision tree machine learning technique[M]//Intelligent Healthcare: Infrastructure, Algorithms and Management[J]</source>. <publisher-loc>Singapore</publisher-loc>: <publisher-name>Springer Nature Singapore</publisher-name>, <year>2022</year>: <fpage>61</fpage>&#x02013;<lpage>83</lpage>.</mixed-citation></ref><ref id="pone.0310410.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Seo</surname><given-names>H</given-names></name>, <name><surname>Brand</surname><given-names>L</given-names></name>, <name><surname>Barco</surname><given-names>LS</given-names></name>, <etal>et al</etal>. <article-title>Scaling multi-instance support vector machine to breast cancer detection on the BreaKHis dataset[J]</article-title>. <source>Bioinformatics</source>, <year>2022</year>, <volume>38</volume>(<issue>1</issue>): <fpage>92</fpage>&#x02013;<lpage>100</lpage>.</mixed-citation></ref><ref id="pone.0310410.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Ak</surname><given-names>MF</given-names></name>. <article-title>A comparative analysis of breast cancer detection and diagnosis using data visualization and machine learning applications[C]//Healthcare[J]</article-title>. <source>MDPI</source>, <year>2020</year>, <volume>8</volume>(<issue>2</issue>): <fpage>111</fpage>&#x02013;<lpage>112</lpage>.</mixed-citation></ref><ref id="pone.0310410.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Sharma</surname><given-names>A</given-names></name>, <name><surname>Mishra</surname><given-names>PK</given-names></name>. <article-title>Performance analysis of machine learning based optimized feature selection approaches for breast cancer diagnosis[J]</article-title>. <source>International Journal of Information Technology</source>, <year>2022</year>: <fpage>1</fpage>&#x02013;<lpage>12</lpage>.</mixed-citation></ref><ref id="pone.0310410.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Binsaif</surname><given-names>N.</given-names></name>
<article-title>Application of machine learning models to the detection of breast cancer[J]</article-title>. <source>Mobile Information Systems</source>, <year>2022</year>: <fpage>7340689</fpage>.</mixed-citation></ref><ref id="pone.0310410.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Kourou</surname><given-names>K</given-names></name>, <name><surname>Exarchos</surname><given-names>TP</given-names></name>, <name><surname>Exarchos</surname><given-names>KP</given-names></name>, <etal>et al</etal>. <article-title>Machine learning applications in cancer prognosis and prediction[J]</article-title>. <source>Computational and structural biotechnology journal</source>, <year>2015</year>, <volume>13</volume>: <fpage>8</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">25750696</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Chaabene</surname><given-names>WB</given-names></name>, <name><surname>Flah</surname><given-names>M</given-names></name>, <name><surname>Nehdi</surname><given-names>ML</given-names></name>. <article-title>Machine learning prediction of mechanical properties of concrete: Critical review[J]</article-title>. <source>Construction and Building Materials</source>, <year>2020</year>, <volume>260</volume>: <fpage>119889</fpage>.</mixed-citation></ref><ref id="pone.0310410.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>XIANG</surname><given-names>YT</given-names></name>,<name><surname>WANG</surname><given-names>M</given-names></name>, <name><surname>CAO</surname><given-names>L</given-names></name>. <article-title>Financial risk prediction method based on multi-objective deep learning model[J]</article-title>. <source>Statistics&#x00026;Decision</source>, <year>2022</year>, <volume>38</volume>(<issue>10</issue>): <fpage>184</fpage>&#x02013;<lpage>188</lpage>.</mixed-citation></ref><ref id="pone.0310410.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>WAN</surname><given-names>LY</given-names></name>. <article-title>Educational forecasting in the age of algorithms and the transformation of its research paradigm[J]</article-title>. <source>Journal of Distance Education</source>, <year>2022</year>, <volume>40</volume>(<issue>3</issue>): <fpage>35</fpage>&#x02013;<lpage>44</lpage>.</mixed-citation></ref><ref id="pone.0310410.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Anisha</surname><given-names>PR</given-names></name>, <name><surname>Reddy</surname><given-names>CKK</given-names></name>, <name><surname>Apoorva</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Early Diagnosis of Breast Cancer Prediction using Random Forest Classifier(C)//IOP Conference Series: Materials Science and Engineering[J]</article-title>. <source>IOP Publishing</source>, <year>2021</year>, <volume>1116</volume>(<issue>1</issue>): <fpage>012187</fpage>.</mixed-citation></ref><ref id="pone.0310410.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Aroef</surname><given-names>C</given-names></name>, <name><surname>Rivan</surname><given-names>Y</given-names></name>, <name><surname>Rustam</surname><given-names>Z</given-names></name>. <article-title>Comparing random forest and support vector machines for breast cancer classification[J]</article-title>. <source>TELKOMNIKA (Telecommunication Computing Electronics and Control)</source>, <year>2020</year>, <volume>18</volume>(<issue>2</issue>): <fpage>815</fpage>&#x02013;<lpage>821</lpage>.</mixed-citation></ref><ref id="pone.0310410.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Cocco</surname><given-names>D</given-names></name>, <name><surname>ElSherif</surname><given-names>A</given-names></name>, <name><surname>Wright</surname><given-names>MD</given-names></name>, <etal>et al</etal>. <article-title>Invasive lobular breast cancer: data to support surgical decision making[J]</article-title>. <source>Annals of surgical oncology</source>, <year>2021</year>, <volume>28</volume>: <fpage>5723</fpage>&#x02013;<lpage>5729</lpage>.<pub-id pub-id-type="pmid">34324111</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Chaffer</surname><given-names>CL</given-names></name>, <name><surname>Weinberg</surname><given-names>RA</given-names></name>. <article-title>A perspective on cancer cell metastasis[J]</article-title>. <source>science</source>, <year>2011</year>, <volume>331</volume>(<issue>6024</issue>): <fpage>1559</fpage>&#x02013;<lpage>1564</lpage>.<pub-id pub-id-type="pmid">21436443</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Ahuja</surname><given-names>A</given-names></name>, <name><surname>Al-Zogbi</surname><given-names>L</given-names></name>, <name><surname>Krieger</surname><given-names>A</given-names></name>. <article-title>Application of noise-reduction techniques to machine learning algorithms for breast cancer tumor identification[J]</article-title>. <source>Computers in Biology and Medicine</source>, <year>2021</year>, <volume>135</volume>: <fpage>104576</fpage>.<pub-id pub-id-type="pmid">34246158</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>M</given-names></name>, <name><surname>Liu</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Clinical big data and deep learning: Applications, challenges, and future outlooks[J]</article-title>. <source>Big Data Mining and Analytics</source>, <year>2019</year>, <volume>2</volume>(<issue>4</issue>): <fpage>288</fpage>&#x02013;<lpage>305</lpage>.</mixed-citation></ref><ref id="pone.0310410.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Yokoyama</surname><given-names>S</given-names></name>, <name><surname>Hamada</surname><given-names>T</given-names></name>, <name><surname>Higashi</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Predicted Prognosis of Patients with Pancreatic Cancer by Machine LearningPrognosis of Pancreatic Cancer by Machine Learning[J]</article-title>. <source>Clinical cancer research</source>, <year>2020</year>, <volume>26</volume>(<issue>10</issue>): <fpage>2411</fpage>&#x02013;<lpage>2421</lpage>.<pub-id pub-id-type="pmid">31992588</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>YY</given-names></name>, <name><surname>Chen</surname><given-names>LP</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Integrated transcriptomic analysis reveals hub genes involved in diagnosis and prognosis of pancreatic cancer[J]</article-title>. <source>Molecular Medicine</source>, <year>2019</year>, <volume>25</volume>(<issue>1</issue>): <fpage>1</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">30616543</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Botsikas</surname><given-names>D</given-names></name>, <name><surname>Bagetakos</surname><given-names>I</given-names></name>, <name><surname>Picarra</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N-and M-staging of breast cancer?[J]</article-title>. <source>European radiology</source>, <year>2019</year>, <volume>29</volume>: <fpage>1787</fpage>&#x02013;<lpage>1798</lpage>.<pub-id pub-id-type="pmid">30267154</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>WC</given-names></name>, <name><surname>Li</surname><given-names>MX</given-names></name>, <name><surname>Qian</surname><given-names>WX</given-names></name>, <etal>et al</etal>. <article-title>Application of machine learning techniques to predict bone metastasis in patients with prostate cancer[J]</article-title>. <source>Cancer Manag Res</source>, <year>2021</year>, <volume>13</volume>: <fpage>23</fpage>&#x02013;<lpage>36</lpage>.</mixed-citation></ref><ref id="pone.0310410.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>P</given-names></name>, <name><surname>Fu</surname><given-names>B</given-names></name>, <name><surname>Yang</surname><given-names>SX</given-names></name>, <etal>et al</etal>. <article-title>Optimizing survival analysis of XGBoost for ties to predict disease progression of breast cancer[J]</article-title>. <source>IEEE Transactions on Biomedical Engineering</source>, <year>2020</year>, <volume>68</volume>(<issue>1</issue>): <fpage>148</fpage>&#x02013;<lpage>160</lpage>.<pub-id pub-id-type="pmid">32406821</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref039"><label>39</label><mixed-citation publication-type="other">Prastyo PH, Paramartha IGY, Pakpahan MM, et al. Predicting breast cancer: A comparative analysis of machine learning algorithms[C]. Proceeding International Conference on Science and Engineering, 2020, 3: 455&#x02013;459.</mixed-citation></ref><ref id="pone.0310410.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>W</given-names></name>, <name><surname>Lee</surname><given-names>M</given-names></name>, <name><surname>Wu</surname><given-names>SN</given-names></name>, <etal>et al</etal>. <article-title>Using machine learning methods to predict bone metastases in breast infiltrating ductal carcinoma patients[J]</article-title>. <source>Frontiers in Public Health</source>, <year>2022</year>: <fpage>2109</fpage>.</mixed-citation></ref><ref id="pone.0310410.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Schettini</surname><given-names>F</given-names></name>, <name><surname>Chic</surname><given-names>N</given-names></name>, <name><surname>Bras&#x000f3;-Maristany</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer[J]</article-title>. <source>NPJ breast cancer</source>, <year>2021</year>, <volume>7</volume>(<issue>1</issue>): <fpage>1</fpage>&#x02013;<lpage>2</lpage>.<pub-id pub-id-type="pmid">33397968</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>H</given-names></name>, <name><surname>Katerji</surname><given-names>H</given-names></name>, <name><surname>Turner</surname><given-names>BM</given-names></name>, <etal>et al</etal>. <article-title>HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles[J]</article-title>. <source>Modern Pathology</source>, <year>2022</year>, <volume>35</volume>(<issue>8</issue>): <fpage>1075</fpage>&#x02013;<lpage>1082</lpage>.<pub-id pub-id-type="pmid">35184150</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Guven</surname><given-names>DC</given-names></name>, <name><surname>Kaya</surname><given-names>MB</given-names></name>, <name><surname>Fedai</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>HER2-low breast cancer could be associated with an increased risk of brain metastasis[J]</article-title>. <source>International Journal of Clinical Oncology</source>, <year>2021</year>: <fpage>1</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="pone.0310410.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Qi</surname><given-names>X</given-names></name>, <name><surname>Du</surname><given-names>J</given-names></name>, <name><surname>Tang</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Clinical significance of internal mammary lymph node metastasis for breast cancer: analysis of 337 breast cancer patients[J]</article-title>. <source>Surgical Oncology</source>, <year>2018</year>, <volume>27</volume>(<issue>2</issue>): <fpage>185</fpage>&#x02013;<lpage>191</lpage>.<pub-id pub-id-type="pmid">29937170</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Yazdani</surname><given-names>A</given-names></name>, <name><surname>Dorri</surname><given-names>S</given-names></name>, <name><surname>Atashi</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Bone metastasis prognostic factors in breast cancer[J]</article-title>. <source>Breast Cancer</source>, <year>2019</year>, <volume>13</volume>:1178223419830978.</mixed-citation></ref><ref id="pone.0310410.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Poortmans</surname><given-names>PM</given-names></name>, <name><surname>Collette</surname><given-names>S</given-names></name>, <name><surname>Kirkove</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Internal mammary and medial supraclavicular irradiation in breast cancer[J]</article-title>. <source>New England Journal of Medicine</source>, <year>2015</year>, <volume>373</volume>(<issue>4</issue>): <fpage>317</fpage>&#x02013;<lpage>327</lpage>.<pub-id pub-id-type="pmid">26200978</pub-id>
</mixed-citation></ref><ref id="pone.0310410.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>SE</given-names></name>, <name><surname>Yoon</surname><given-names>JH</given-names></name>, <name><surname>Son</surname><given-names>NH</given-names></name>, <etal>et al</etal>. <article-title>Screening in Patients With Dense Breasts: Comparison of Mammography, Artificial Intelligence, and Supplementary Ultrasound[J]</article-title>. <source>American Journal of Roentgenology</source>, <year>2023</year>: <fpage>1</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">36542746</pub-id>
</mixed-citation></ref></ref-list></back><sub-article article-type="aggregated-review-documents" id="pone.0310410.r001" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0310410.r001</article-id><title-group><article-title>Decision Letter 0</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Srinivasan</surname><given-names>Kathiravan</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Kathiravan Srinivasan</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Kathiravan Srinivasan</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0310410" id="rel-obj001" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">9 Aug 2023</named-content>
</p><p><!-- <div> -->PONE-D-23-20544<!-- </div> --><!-- <div> -->Machine learning-based prediction of distance metastasis risk in invasive ductal carcinoma of the breast<!-- </div> --><!-- <div> -->PLOS ONE</p><p>Dear Dr. Zhang,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#x02019;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>==============================</p><p>ACADEMIC EDITOR: Please revise and resubmit your manuscript. &#x000a0;</p><p>==============================</p><p>Please submit your revised manuscript by Sep 23 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at&#x000a0;<email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:<!-- </div> --><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list></p><p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols</ext-link>.</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Kathiravan Srinivasan</p><p>Academic Editor</p><p>PLOS ONE</p><p>Journal Requirements:</p><p>When submitting your revision, we need you to address these additional requirements.</p><p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at&#x000a0;</p><p><ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and&#x000a0;</p><p>
<ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>
</p><p>2. Please note that PLOS ONE has specific guidelines on code sharing for submissions in which author-generated code underpins the findings in the manuscript. In these cases, all author-generated code must be made available without restrictions upon publication of the work. Please review our guidelines at <ext-link xlink:href="https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code" ext-link-type="uri">https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code</ext-link> and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse.</p><p>3. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to &#x02018;Update my Information&#x02019; (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: <ext-link xlink:href="https://www.youtube.com/watch?v=_xcclfuvtxQ" ext-link-type="uri">https://www.youtube.com/watch?v=_xcclfuvtxQ</ext-link></p><p>4. Please clarify the Figure 8 "Fig 8. Receiver operating characteristic of each prediction model" in page "15" and Figure 8 "Fig 8. Box plot of mean and standard deviation for each indicator" in page "15".</p><p>5. Please upload a copy of Figures 11,12 and 13, to which you refer in your text on page. If 16 and 19the figure is no longer to be included as part of the submission please remove all reference to it within the text.</p><p>6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <ext-link xlink:href="http://journals.plos.org/plosone/s/supporting-information" ext-link-type="uri">http://journals.plos.org/plosone/s/supporting-information</ext-link>.&#x000a0;</p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>
<!-- <font color="black"> -->
<bold>Comments to the Author</bold>
</p><p>1. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. <!-- </font> --></p><p>Reviewer #1:&#x000a0;Partly</p><p>Reviewer #2:&#x000a0;Partly</p><p>Reviewer #3:&#x000a0;Yes</p><p>Reviewer #4:&#x000a0;Partly</p><p>Reviewer #5:&#x000a0;No</p><p>Reviewer #6:&#x000a0;Partly</p><p>**********</p><p><!-- <font color="black"> -->2. Has the statistical analysis been performed appropriately and rigorously? <!-- </font> --></p><p>Reviewer #1:&#x000a0;No</p><p>Reviewer #2:&#x000a0;N/A</p><p>Reviewer #3:&#x000a0;Yes</p><p>Reviewer #4:&#x000a0;Yes</p><p>Reviewer #5:&#x000a0;No</p><p>Reviewer #6:&#x000a0;I Don't Know</p><p>**********</p><p><!-- <font color="black"> -->3. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#x02014;e.g. participant privacy or use of data from a third party&#x02014;those must be specified.<!-- </font> --></p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;Yes</p><p>Reviewer #3:&#x000a0;Yes</p><p>Reviewer #4:&#x000a0;Yes</p><p>Reviewer #5:&#x000a0;No</p><p>Reviewer #6:&#x000a0;No</p><p>**********</p><p><!-- <font color="black"> -->4. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.<!-- </font> --></p><p>Reviewer #1:&#x000a0;No</p><p>Reviewer #2:&#x000a0;Yes</p><p>Reviewer #3:&#x000a0;Yes</p><p>Reviewer #4:&#x000a0;Yes</p><p>Reviewer #5:&#x000a0;Yes</p><p>Reviewer #6:&#x000a0;No</p><p>**********</p><p><!-- <font color="black"> -->5. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)<!-- </font> --></p><p>Reviewer #1:&#x000a0;The study's results were affected by the restricted data availability in terms of regional representation, limited quantity, and subjective feature selection.</p><p>-In the context of limited data in this study, data augmentation can be a valuable technique to overcome the scarcity of samples and improve the performance of machine learning models. Data augmentation involves creating additional training examples by applying various transformations to the existing data, while preserving the label information.</p><p>For your study, in the case of breast cancer data, data augmentation techniques can be applied to medical images (such as mammograms or MRI scans) to create new images with subtle modifications. These modifications may include rotation, flipping, zooming, translation, or adding noise, among others. By applying such transformations, the dataset can be expanded, enabling the models to learn from a broader range of scenarios.</p><p>-In addition to addressing the issue of overfitting, it is essential to thoroughly investigate and fine-tune your model's learning rates.</p><p>Reviewer #2:&#x000a0;Journal: PLOS ONE</p><p>Manuscript Title: Machine learning-based prediction of distance metastasis risk in invasive ductal carcinoma of the breast</p><p>Manuscript ID: PONE-D-23-20544</p><p>Submission Date: Sunday, July 30, 2023</p><p>The manuscript presented &#x0201c;a prediction approach of distance metastasis risk in invasive ductal carcinoma of the breast&#x0201d;. However, the major and critical weak points are that:</p><p>(1)Their proposed work discussion is weak distributed to be described or analyzed.</p><p>(2)The novelty is not guaranteed.</p><p>(3)Their experiments leak from the descriptive and statistical analysis.</p><p>The rest of my review presents other weak points, comments, and opinions in detail.</p><p>Overall Comments:</p><p>(1)[KEYWORDS] The keywords (i.e., index terms) should be sorted in alphabetical order.</p><p>(2)[ABSTRACT] The abstract should contain the best-achieved results from the performed experiments.</p><p>(3)[ABSTRACT] The abstract should reflect the contributions of the manuscript. I suggest rewriting it.</p><p>(4)[INTRODUCTION] The authors should provide a clear problem definition and contributions in the introduction section.</p><p>(5)[RESEARCH QUESTION] Where is the research question and research gap?</p><p>(6)[RESEARCH QUESTION] The research question is not well-formulated or is poorly motivated, and the paper does not provide new insights or information that is not already known.</p><p>(7)[RELATED WORK] Where are the related studies? They should be declared in a separate section.</p><p>(8)[RELATED WORK] A table of comparisons should be added at the end of the related studies section to praise the pros. and cons. of them. The year column should be added and they should be ordered by it.</p><p>(9)[EQUATIONS] The authors should follow the journal authors&#x02019; guidance in writing the equations, symbols, and variables. Please, refer to the authors guidelines on the journal official website.</p><p>(10)[EQUATIONS] Where are the equations of the used metrics?</p><p>(11)[DATASETS] Samples from the used dataset should be added and annotated.</p><p>(12)[METHODOLOGY] The suggested approach is not clearly discussed. More scientific details should be added.</p><p>(13)[METHODOLOGY] What are the used equations in the suggested approach? In other words, how the suggested approach is derived?</p><p>(14)[METHODOLOGY] Where is the overall pseudocode? Flowchart? of the suggested approach?</p><p>(15)[EXPERIMENTS] The working environment (i.e., software and hardware) should be declared and added to a table.</p><p>(16)[EXPERIMENTS] The experimental configurations (i.e., settings) should be declared and added to a table.</p><p>(17)[EXPERIMENTS] What are the criteria for selecting the experimental configurations?</p><p>(18)[EXPERIMENTS] More experiments should be conducted using different configurations.</p><p>(19)[EXPERIMENTS] Where is the tabular representation of the reported results?</p><p>(20)[EXPERIMENTS] Why did not the authors compare their approach with others in a table?</p><p>(21)[EXPERIMENTS] Why did not the authors compare their approach with another approach to compare the suggested approach efficiency and applicability?</p><p>(22)[EXPERIMENTS] Where is the detailed and statistical discussion of the reported results?</p><p>(23)[EXPERIMENTS] More experiments should be conducted using a different dataset to prove the generalization.</p><p>(24)The manuscript does not provide a clear contribution to the field of research.</p><p>(25)The manuscript does not provide a clear justification for the research.</p><p>(26)[RESULTS] The authors have not provided adequate visual aids, such as graphs or tables, to help readers understand the data.</p><p>(27)[ABBREVIATIONS] The authors should add a table of abbreviations in the revised manuscript.</p><p>(28)[SYMBOLS] The authors should add a table of symbols in the revised manuscript.</p><p>(29)[CONCLUSIONS] The conclusions in this manuscript are primitive. Please, write your conclusions.</p><p>(30)[REFERENCES] There are no citations for many sentences in the manuscript. Why? Please check.</p><p>(31)[REFERENCES] The references should be written in the same style following the journal authors&#x02019; guidance.</p><p>(32)[REFERENCES] Recent citations from 2021 and 2022 should be added to the manuscript.</p><p>(33)[PROOFING] The authors should get editing help from someone with full professional proficiency in English.</p><p>(34)[PROOFING] The manuscript should be checked again to fix any typos such as missing spaces and commas.</p><p>(35)[CONSISTENCY] The manuscript structure is too short. It must be elaborated in their applied technology as should support more rigorous technical aspects.</p><p>(36)[CONSISTENCY] Some paragraphs are wrapped in more than 10 lines. They should be split concisely.</p><p>(37)[NOVELTY] What is the novelty of the suggested approach?</p><p>(38)[LIMITATIONS] What are the limitations of the current study? It should be added in a separate section.</p><p>For the authors in case of the authors got a chance to review the manuscript and submit the revised one after the editor&#x02019;s decision, please, provide a table in the revised manuscript mentioning (1) the comment, (2) the authors&#x02019; response, and (3) the authors&#x02019; change (if applicable). Please, consider all of the comments and don&#x02019;t ignore any of them.</p><p>Please, refer to the attached file "PONE-D-23-20544 Reviewer.pdf" for the same comments in an organized format.</p><p>Reviewer #3:&#x000a0;Considering the type of study that is retrospective, the project has no ethical problems.</p><p>Your project is excellent and I hope that it will increase the life expectancy of cancer patients in the future.</p><p>Reviewer #4:&#x000a0;First of all, I would like to thanks authors for the efforts they made to make this contribution. The subject is very interesting and has a very relevant impact on society.</p><p>Authors try to deal with the metastasis risk in invasive ductal carcinoma of the breast using machine learning techniques,</p><p>We have many questions and remarks about the contribution :</p><p>- The paper is well-written and easily understandable.</p><p>- Authors gave a big part to the Model's definition and presentation, We think they should revisit this part to make it smaller, all the used algorithms are well known.</p><p>- A part of the dataset presentation is essential to simplify the problem understanding and make the model's interpretation significant and efficient.</p><p>- Are all features important? If Yes why? If No why authors didn't look for a features selection method to optimize the learning process and complexity?</p><p>- We think that the authors have to explain more about the added value and the importance of using machine learning in this problem and how their solution can help doctors.</p><p>- We recommend that the literature review be in a table containing recent works on the same topics, used models, results, and limitations</p><p>- Authors have to present all models configuration, that make the research reproduction possible</p><p>- All used features should be clearly presented</p><p>- We recommend the use of a schema to present the research process</p><p>Wishing all the best for the upcoming research</p><p>Reviewer #5:&#x000a0;The overall idea of the manuscript to predict the risk of distant organ metastases is good, but the manuscript is not written well and has some flaws:</p><p>- The authors did not provide a list of features used to train their model. They need to show the name, type, and specification of features in a table.</p><p>- The authors mentioned that they used an 8:2 ratio to split the database into train/test sets, but they did not report any results on the model's performance on the 20% unseen test dataset.</p><p>- The authors mentioned in some parts of the manuscript that their original dataset was unbalanced, and they used an undersampling approach to address this issue. However, they did not provide any information on the original size of the dataset or the size of the dataset after downsampling.</p><p>- In line 114, the authors mentioned that they used a "small number of features" to train their model. What are the names of these features? They need to be shown in a table.</p><p>- The authors claimed that they wanted to predict the "risk" of distant metastases, yet it seems that the models they trained are binary models that have 0/1 output. Usually, for risk prediction, the model needs to have a continuous output to show the probability of an event.</p><p>- In Figure 4, what do M0 and M1 represent?</p><p>- In Figure 5, the details of the features need to be made clear in a table, as mentioned in the comment above.</p><p>- In Figure 6, the confusion matrix needs to be shown in normalized form to make it more readable.</p><p>- In Figure 8, a table should be used instead of a figure.</p><p>- In line 249, the authors mentioned that they ranked the importance of 14 features. How did they choose these 14 features?</p><p>- In line 327, the authors mentioned that there are a few studies that have done the same work. They should reference these studies in their manuscript and compare their approach with theirs.</p><p>Reviewer #6:&#x000a0;The authors used random forest, XGBoost, logical regression, and support vector machine (SVM) to construct risk prediction models to build a fusion model based on the voting mechanism to develop a prediction model to determine the risk of distant organ metastasis in invasive ductal carcinoma (IDC). Several concerns are raised with this research that should be considered by the authors.</p><p>(1)This article's main concern is its innovation. In what way does this research innovate? There have been a lot of studies using the mentioned machine learning models, and the idea of voting is not new. What makes the introduced method superior?</p><p>(2)As I read the article, my initial thought was to find a reason, based on the topic's attractiveness, why this article might attract readers. Unfortunately, I didn't find the article to be well organized and I was not justified in reading it.</p><p>(3)Despite the fact that a lot of research has been conducted in this field, the authors did not compare other methods. As a result, it cannot be justified.</p><p>(4)The abstract of the article has not been prepared properly. The abstract should begin with a short introduction containing the assumption and challenge of the problem, followed by the proposed method to solve the problem, the results (quantitatively and qualitatively), and the conclusion.</p><p>(5)There is a lack of clarity and depth in the introduction related work. The authors should organize them professionally. Furthermore, the references are outdated.</p><p>(6)Does the authors' assertion that they implemented the method on this dataset justify the method's generalizability?</p><p>(7)Results are poorly presented. Can the classification process be affected by changing parameters? Both qualitative and quantitative results are desired by the reader.</p><p>(8)The article should be carefully revised by the authors and possible typos and writing errors should be corrected.</p><p>(9)In order to understand the disadvantages of the proposed method, it is recommended to include some figures showing that the proposed method does not produce the expected results. It is also better to mention the disadvantages of the proposed method.</p><p>(10)The figures (e.g., Figures 8 and 10) are of poor quality. The authors should include more high-quality figures in the text. It is possible to save images in EMF format to ensure better quality.</p><p>(11)There will be a better version of this work with better preparation, such as comparative results, different method output figures, etc.</p><p>(12)The article appears to have been written in a hurry, has a low level of innovation, and unfortunately, the professor supervisor did not check the article thoroughly. Although this research has some basic flaws, I believe it still faces some basic challenges.</p><p>**********</p><p><!-- <font color="black"> -->6. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#x0201c;no&#x0201d;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.<!-- </font> --></p><p>Reviewer #1:&#x000a0;No</p><p>Reviewer #2:&#x000a0;<bold>Yes:&#x000a0;</bold>Hossam Balaha</p><p>Reviewer #3:&#x000a0;No</p><p>Reviewer #4:&#x000a0;No</p><p>Reviewer #5:&#x000a0;No</p><p>Reviewer #6:&#x000a0;No</p><p>**********</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool,&#x000a0;<ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at&#x000a0;<email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p><supplementary-material id="pone.0310410.s002" position="float" content-type="local-data"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">PONE-D-23-20544 Reviewer.pdf</named-content></p></caption><media xlink:href="pone.0310410.s002.pdf"/></supplementary-material><supplementary-material id="pone.0310410.s003" position="float" content-type="local-data"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">PONE-D-23-20544_reviewer (3).pdf</named-content></p></caption><media xlink:href="pone.0310410.s003.pdf"/></supplementary-material></body></sub-article><sub-article article-type="author-comment" id="pone.0310410.r002"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0310410.r002</article-id><title-group><article-title>Author response to Decision Letter 0</article-title></title-group><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0310410" id="rel-obj002" related-article-type="editor-report"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">30 Sep 2023</named-content>
</p><p>Dear reviewer:</p><p>Thank you very much for your comments and professional advice. These opinions help to improve academic rigor of our article. Based on your suggestion and request, we have made corrected modifications on the revised manuscript. Meanwhile, the manuscript had be reviewed and edited by language services of EDITAGE. We hope that our work can be improved again. Furthermore, we would like to show the details as follows:</p><p>Reviewer 1#</p><p>1.In the context of limited data in this study, data augmentation can be a valuable technique to overcome the scarcity of samples and improve the performance of machine learning models. Data augmentation involves creating additional training examples by applying various transformations to the existing data, while preserving the label information.</p><p>For your study, in the case of breast cancer data, data augmentation techniques can be applied to medical images (such as mammograms or MRI scans) to create new images with subtle modifications. These modifications may include rotation, flipping, zooming, translation, or adding noise, among others. By applying such transformations, the dataset can be expanded, enabling the models to learn from a broader range of scenarios.</p><p>The author&#x02019;s answer: Thank you very much for your professional and valuable feedback. We also believe that applying it to images is very meaningful, and we will also consider doing so. However, due to limited research conditions at present. We do not have more relevant data for analysis. In the following research, we will consider expanding the dataset and applying it to a wider range of studies.</p><p>2.In addition to addressing the issue of overfitting, it is essential to thoroughly investigate and fine-tune your model's learning rates.</p><p>The author&#x02019;s answer: Thank you very much for your professional advice. In our study, we used different indicators including accuracy, precision, recall, AUC value, F1 value, etc. to evaluate the learning effectiveness of the model. The specific research results are presented in 3.4 Model Performance. In addition, we used undersampling to solve the problem of model overfitting, and then used learning curves to evaluate the final fitting effect.</p><p>Reviewer 2#</p><p>1.[KEYWORDS] The keywords (i.e., index terms) should be sorted in alphabetical order.</p><p>The author&#x02019;s answer: Thank you for pointing this out. The keywords has been sorted alphabetically and modified.</p><p>2.[ABSTRACT] The abstract should contain the best-achieved results from the performed experiments.</p><p>3.[ABSTRACT] The abstract should reflect the contributions of the manuscript. I suggest rewriting it.</p><p>The author&#x02019;s answer: Thank you for your suggestion. We have rewritten the abstract section, which includes the best results of the experiments conducted and reflects the contributions of the manuscript. The changes to the manuscript are given in the blue text.</p><p>4.[INTRODUCTION] The authors should provide a clear problem definition and contributions in the introduction section.</p><p>The author&#x02019;s answer: Thank you for your professional suggestion. We have made changes to the introduction and provided a definition of the problem, and we provided the contributions of the manuscript at the end of the introduction. The changes and additions to the introduction are given in the yellow text.</p><p>5.[RESEARCH QUESTION] Where is the research question and research gap?</p><p>6.[RESEARCH QUESTION] The research question is not well-formulated or is poorly motivated, and the paper does not provide new insights or information that is not already known.</p><p>The author&#x02019;s answer: Thank you very much for your professional and valuable feedback. We propose a research gap in the fourth paragraph of the introduction. We have compared (Table 1) with other relevant studies to reflect the current research gap in predicting the risk of IDC cancer metastasis. At the same time, we have proposed our scientific questions to fill this research gap. The changes to the manuscript are given in the yellow text.</p><p>7.[RELATED WORK] Where are the related studies? They should be declared in a separate section.</p><p>8.[RELATED WORK] A table of comparisons should be added at the end of the related studies section to praise the pros. and cons. of them. The year column should be added and they should be ordered by it.</p><p>The author&#x02019;s answer: Thank you very much for your professional and valuable advice. After reading and consulting many literatures, we sorted out the research of machine learning on breast cancer prediction. We present it in the manuscript through Table 1.</p><p>9.[EQUATIONS] The authors should follow the journal authors&#x02019; guidance in writing the equations, symbols, and variables. Please, refer to the authors guidelines on the journal official website.</p><p>10.[EQUATIONS] Where are the equations of the used metrics?</p><p>The author&#x02019;s answer: Thanks for your careful checks. Based on your comments, we have made the corrections to make the equations conform to the journal author's guide. The equation for the indicators used is given in the section '2.4 Evaluation indicators'.</p><p>11.[DATASETS] Samples from the used dataset should be added and annotated.</p><p>The author&#x02019;s answer: Thank you for your comments. We have submitted all datasets in the attachment, including raw data, datasets after inclusion and exclusion criteria, training and testing dataset samples, and undersampling dataset samples.</p><p>12.[METHODOLOGY] The suggested approach is not clearly discussed. More scientific details should be added.</p><p>13.[METHODOLOGY] What are the used equations in the suggested approach? In other words, how the suggested approach is derived?</p><p>14.[METHODOLOGY] Where is the overall pseudocode? Flowchart? of the suggested approach?</p><p>The author&#x02019;s answer: We sincerely appreciate the valuable comments. We discussed the proposed method in detail in '2.3 Model Establishment', adding some scientific details and main equations (Equation 2). The overall pseudo code is presented in Table 5.</p><p>15.[EXPERIMENTS] The working environment (i.e., software and hardware) should be declared and added to a table.</p><p>16.[EXPERIMENTS] The experimental configurations (i.e., settings) should be declared and added to a table.</p><p>17.[EXPERIMENTS] What are the criteria for selecting the experimental configurations?</p><p>18.[EXPERIMENTS] More experiments should be conducted using different configurations.</p><p>19.[EXPERIMENTS] Where is the tabular representation of the reported results?</p><p>20.[EXPERIMENTS] Why did not the authors compare their approach with others in a table?</p><p>21.[EXPERIMENTS] Why did not the authors compare their approach with another approach to compare the suggested approach efficiency and applicability?</p><p>22.[EXPERIMENTS] Where is the detailed and statistical discussion of the reported results?</p><p>23.[EXPERIMENTS] More experiments should be conducted using a different dataset to prove the generalization.</p><p>The author&#x02019;s answer: We sincerely appreciate the valuable comments. For the 'EXPERIMENTS' question, we provide the following answers: </p><p>[15-16] The experimental environment configuration, detailed information on the software package used for machine learning model development, and basic learner parameters information are added to Tables 3, 4, and 6, respectively.</p><p>[17] The criteria for selecting experimental configurations are to strive to achieve optimal model performance by setting the above parameters during model training.</p><p>[18] We used different parameters to conduct more experiments during the code running process, and ultimately presented the best results in the article.</p><p>[19] Thank you very much for your proposal. We have added Tables 7, 8, and 9 to the results section to illustrate the distribution information of the data. Figures 5-8 are the main results of evaluating and comparing the performance of the model.</p><p>[20-21] Thank you very much for your professional and valuable advice. After reading and consulting many literatures, we sorted out the research of machine learning on breast cancer prediction. We present it in the manuscript through Table 1.</p><p>[22] Thank you for your comments. We conducted a more detailed and in-depth discussion on the results of the report in the discussion section. We updated the background description of breast cancer with reference to the latest literature (273-278 lines); We reorganize and analyze the results (lines 300-322); Discuss in detail the results of univariate and multivariate logistic regression analysis (lines 343-367). The additions to the discussion are given in the red text, and the changes to the discussion are given in the green text.</p><p>[23] We appreciate your careful reading of our manuscript and your professional feedback. We tested the model in our study using data from only 20% of the internal test set. There is no external dataset to validate it, which is the main limitation of this study. We strongly agree to use some external data to validate our model. We apologize for the fact that there is currently no available data to conduct the experiments. We will definitely address this limitation in the future if we have the opportunity.</p><p>24.The manuscript does not provide a clear contribution to the field of research.</p><p>The author&#x02019;s answer: We explained in the last paragraph of the introduction the contribution of the manuscript to the research field. The additions to the discussion are given in the blue text(lines 292-299).</p><p>25.The manuscript does not provide a clear justification for the research.</p><p>The author&#x02019;s answer: Thank you very much for your question. Our study aims to establish an efficient machine learning model to predict the risk of cancer metastasis in IDC patients. Thereby assisting clinicians in making more rational clinical decisions and enabling patients to receive treatment earlier, which is useful for breast surgeons to quickly and accurately determine whether cancer metastasis has occurred in patients with IDC. We have introduced both the introduction and discussion sections. In addition, we also focused on the performance of single machine learning models and multi algorithm fusion machine learning models, and found that the fusion model has stronger learning performance.</p><p>[RESULTS] The authors have not provided adequate visual aids, such as graphs or tables, to help readers understand the data.</p><p>The author&#x02019;s answer: Thank you very much for your comments. Based on your suggestion, we have added more tables in the article, such as Tables 7-9. Compared to the initial draft, we have added a total of 9 tables as visual aids, which can help readers understand the data.</p><p>26.[ABBREVIATIONS] The authors should add a table of abbreviations in the revised manuscript.</p><p>27.[SYMBOLS] The authors should add a table of symbols in the revised manuscript.</p><p>The author&#x02019;s answer: Thank you for your suggestion. We have added a list of abbreviations (Table 2).</p><p>28.[CONCLUSIONS] The conclusions in this manuscript are primitive. Please, write your conclusions.</p><p>The author&#x02019;s answer: Thank you very much for your comments and professional advice. We have made changes to the conclusion section to make it more concise and highlight the key points.</p><p>29.[REFERENCES] There are no citations for many sentences in the manuscript. Why? Please check.</p><p>30.[REFERENCES] The references should be written in the same style following the journal authors&#x02019; guidance.</p><p>31.[REFERENCES] Recent citations from 2021 and 2022 should be added to the manuscript.</p><p>The author&#x02019;s answer: We are really sorry for our careless mistakes. We have re reviewed the article and corrected this error. Added citation identification to quoted sentences. And modify the reference format according to the requirements of the journal author's guide. Added some latest references from 2021 and 2022. Such as references 1, 2, 13, 18, 23, 30, 33, 35, 36, etc.</p><p>32.[PROOFING] The authors should get editing help from someone with full professional proficiency in English.</p><p>33.[PROOFING] The manuscript should be checked again to fix any typos such as missing spaces and commas.</p><p>The author&#x02019;s answer: Thanks for your careful checks. We are sorry for our carelessness. We first rechecked the manuscript and corrected typos, punctuation errors, and missing spaces. We have invited a professional polishing agency to help polish our manuscript. The editing certification will be provided in the attachment. And we hope the revised manuscript could be acceptable for you.</p><p>34.[CONSISTENCY] The manuscript structure is too short. It must be elaborated in their applied technology as should support more rigorous technical aspects.</p><p>35.[CONSISTENCY] Some paragraphs are wrapped in more than 10 lines. They should be split concisely.</p><p>The author&#x02019;s answer: We greatly appreciate your valuable advice. Based on your suggestion, we have added some article structures. For example, in the results section, we have added '3.1 Demographic characterization' and '3.2 One-way logistic regression analysis' to make the manuscript richer in content and more complete in structure. We have re edited some paragraphs in the manuscript with more than 10 lines to make them concise and concise.</p><p>36.[NOVELTY] What is the novelty of the suggested approach?</p><p>The author&#x02019;s answer: As each learning model has its own advantages and disadvantages. For example, the XGBoost algorithm adds a regular term to the objective function to control the complexity of the model. It makes the learned model simpler and prevents overfitting. However, this modeling algorithm has too many parameters and is complex to tune. On the contrary, random forest learning model training can be highly parallelized, fast training speed, high efficiency. However, it is prone to overfitting in some noisy classification problems and or regression problems. Then, by constructing a machine learning model that fuses several models together, we can maximize the guarantee that this new model has the maximum advantages and minimum disadvantages. In addition, to the best of our knowledge, it is relatively rare to use this model for predicting IDC transfer risk.</p><p>37.[LIMITATIONS] What are the limitations of the current study? It should be added in a separate section.</p><p>The author&#x02019;s answer: The main limitation of this study is that the data used are limited by region, volume and subjectivity of feature selection, which constrains the final experimental results. In addition, this is a retrospective study that needs to be validated by prospective studies. We have placed research limitations in a separate section, see '6 Research limitations' in the manuscript.</p><p>Reviewer 3#</p><p>Considering the type of study that is retrospective, the project has no ethical problems. Your project is excellent and I hope that it will increase the life expectancy of cancer patients in the future.</p><p>The author&#x02019;s answer: Thank you very much for your endorsement of our project. We are very honored by your praise. We have reviewed this article again and carefully revised and supplemented it, making every effort to make it more scientific and rigorous.</p><p>Reviewer 4#</p><p>1.The paper is well-written and easily understandable.</p><p>The author&#x02019;s answer: We feel very honored by your compliments. We have re-examined the article and made careful changes and additions. We'll keep working on it.</p><p>2.Authors gave a big part to the Model's definition and presentation, We think they should revisit this part to make it smaller, all the used algorithms are well known.</p><p>The author&#x02019;s answer: We think this is an excellent suggestion. We have made changes to the presentation part of the model's definition. In the part of the manuscript where the font is marked blue.</p><p>3.A part of the dataset presentation is essential to simplify the problem understanding and make the model's interpretation significant and efficient.</p><p>The author&#x02019;s answer: Thanks for your suggestion. As per your suggestion, we have shown the information about the dataset in the section '3.1 Demographic characterization' through Table 6 and Table 7. In addition, the original dataset information, training set and test set data are uploaded through attachments.</p><p>4.Are all features important? If Yes why? If No why authors didn't look for a features selection method to optimize the learning process and complexity?</p><p>The author&#x02019;s answer: Thank you very much for your question. We explain the issue as follows: </p><supplementary-material id="pone.0310410.s004" position="float" content-type="local-data"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">Response to Reviewers.doc</named-content></p></caption><media xlink:href="pone.0310410.s004.doc"/></supplementary-material></body></sub-article><sub-article article-type="aggregated-review-documents" id="pone.0310410.r003" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0310410.r003</article-id><title-group><article-title>Decision Letter 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Srinivasan</surname><given-names>Kathiravan</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Kathiravan Srinivasan</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Kathiravan Srinivasan</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0310410" id="rel-obj003" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">24 Oct 2023</named-content>
</p><p><!-- <div> -->PONE-D-23-20544R1<!-- </div> --><!-- <div> -->Machine learning-based prediction of distant metastasis risk in invasive ductal carcinoma of the breast<!-- </div> --><!-- <div> -->PLOS ONE</p><p>Dear Dr. Zhang,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#x02019;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>==============================</p><p>ACADEMIC EDITOR: Please revise and resubmit your manuscript..&#x000a0;</p><p>==============================</p><p>Please submit your revised manuscript by Dec 08 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at&#x000a0;<email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:<!-- </div> --><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list><!-- <div> -->If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols</ext-link>.</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Kathiravan Srinivasan</p><p>Academic Editor</p><p>PLOS ONE</p><p>Journal Requirements:</p><p>Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article&#x02019;s retracted status in the References list and also include a citation and full reference for the retraction notice.</p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>
<!-- <font color="black"> -->
<bold>Comments to the Author</bold>
</p><p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the &#x0201c;Comments to the Author&#x0201d; section, enter your conflict of interest statement in the &#x0201c;Confidential to Editor&#x0201d; section, and submit your "Accept" recommendation.<!-- </font> --></p><p>Reviewer #2:&#x000a0;All comments have been addressed</p><p>Reviewer #3:&#x000a0;All comments have been addressed</p><p>Reviewer #5:&#x000a0;All comments have been addressed</p><p>Reviewer #6:&#x000a0;All comments have been addressed</p><p>**********</p><p><!-- <font color="black"> -->2. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. <!-- </font> --></p><p>Reviewer #2:&#x000a0;Yes</p><p>Reviewer #3:&#x000a0;Yes</p><p>Reviewer #5:&#x000a0;Partly</p><p>Reviewer #6:&#x000a0;Yes</p><p>**********</p><p><!-- <font color="black"> -->3. Has the statistical analysis been performed appropriately and rigorously? <!-- </font> --></p><p>Reviewer #2:&#x000a0;No</p><p>Reviewer #3:&#x000a0;I Don't Know</p><p>Reviewer #5:&#x000a0;Yes</p><p>Reviewer #6:&#x000a0;I Don't Know</p><p>**********</p><p><!-- <font color="black"> -->4. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#x02014;e.g. participant privacy or use of data from a third party&#x02014;those must be specified.<!-- </font> --></p><p>Reviewer #2:&#x000a0;Yes</p><p>Reviewer #3:&#x000a0;Yes</p><p>Reviewer #5:&#x000a0;No</p><p>Reviewer #6:&#x000a0;No</p><p>**********</p><p><!-- <font color="black"> -->5. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.<!-- </font> --></p><p>Reviewer #2:&#x000a0;Yes</p><p>Reviewer #3:&#x000a0;Yes</p><p>Reviewer #5:&#x000a0;No</p><p>Reviewer #6:&#x000a0;Yes</p><p>**********</p><p><!-- <font color="black"> -->6. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)<!-- </font> --></p><p>Reviewer #2:&#x000a0;Journal: PLOS ONE</p><p>Manuscript Title: Machine learning-based prediction of distant metastasis risk in invasive ductal carcinoma of the breast</p><p>Manuscript ID: PONE-D-23-20544R1</p><p>Submission Date: Monday, October 9, 2023</p><p>The authors have made a suitable major revision. However, there are some concerns that should be addressed:</p><p>Overall Comments:</p><p>(1)The conclusions need to be enhanced and the future work should be addressed.</p><p>(2)The statistical analysis should be more descriptive.</p><p>(3)The following references can be addressed in your study:</p><p>a.Balaha, H. M., Antar, E. R., Saafan, M. M., &#x00026; El-Gendy, E. M. (2023). A comprehensive framework towards segmenting and classifying breast cancer patients using deep learning and Aquila optimizer. Journal of Ambient Intelligence and Humanized Computing, 14(6), 7897-7917.</p><p>b.Lee, S. E., Yoon, J. H., Son, N. H., Han, K., &#x00026; Moon, H. J. (2023). Screening in Patients With Dense Breasts: Comparison of Mammography, Artificial Intelligence, and Supplementary Ultrasound. American Journal of Roentgenology.</p><p>c.Baghdadi, N. A., Malki, A., Balaha, H. M., AbdulAzeem, Y., Badawy, M., &#x00026; Elhosseini, M. (2022). Classification of breast cancer using a manta-ray foraging optimized transfer learning framework. PeerJ Computer Science, 8, e1054.</p><p>For the authors in case of the authors got a chance to review the manuscript and submit the revised one after the editor&#x02019;s decision, please, provide a table in the revised manuscript mentioning (1) the comment, (2) the authors&#x02019; response, and (3) the authors&#x02019; change (if applicable). Please, consider all of the comments and don&#x02019;t ignore any of them.</p><p>Please, refer to the attached file "PONE-D-23-20544R1 Reviewer.pdf" for the same comments in an organized format.</p><p>Reviewer #3:&#x000a0;According to the corrections that were suggested by different reviewers , this article seems to be suitable for publishing.</p><p>Reviewer #5:&#x000a0;Thanks. I didn't see the "data availability" exploitation in the manuscript. That would be good to add a statement in the manuscript to show how readers can access to the data.</p><p>Reviewer #6:&#x000a0;There have been many solutions to the previous problems. The authors should take care that the responsibility for the results and validation of the results lies with them alone. Figures and references should be carefully reviewed. The references to the equations, as well as the definitions of some of their parameters, should also be carefully checked.</p><p>**********</p><p><!-- <font color="black"> -->7. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#x0201c;no&#x0201d;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.<!-- </font> --></p><p>Reviewer #2:&#x000a0;<bold>Yes:&#x000a0;</bold>Hossam Magdy Balaha</p><p>Reviewer #3:&#x000a0;No</p><p>Reviewer #5:&#x000a0;No</p><p>Reviewer #6:&#x000a0;No</p><p>**********</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool,&#x000a0;<ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at&#x000a0;<email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p><supplementary-material id="pone.0310410.s005" position="float" content-type="local-data"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">PONE-D-23-20544R1 Reviewer.pdf</named-content></p></caption><media xlink:href="pone.0310410.s005.pdf"/></supplementary-material></body></sub-article><sub-article article-type="author-comment" id="pone.0310410.r004"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0310410.r004</article-id><title-group><article-title>Author response to Decision Letter 1</article-title></title-group><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0310410" id="rel-obj004" related-article-type="editor-report"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>2</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">15 Jan 2024</named-content>
</p><p>Dear reviewer:</p><p>Thank you very much for your comments and professional advice. These opinions help to improve academic rigor of our article. Based on your suggestion and request, we have made corrected modifications on the revised manuscript. We hope that our work can be improved again. Furthermore, we would like to show the details as follows:</p><p>Reviewer #2</p><p>1.The conclusions need to be enhanced and the future work should be addressed.</p><p>The author&#x02019;s answer: Thank you very much for your professional and valuable feedback. We have rewritten the conclusion section to make it more comprehensive. The changes to the manuscript are given in the blue text. As for the next steps, our primary focus will be on external validation, a task we are actively pursuing.</p><p>2.The statistical analysis should be more descriptive.</p><p>The author&#x02019;s answer: Thank you very much for the positive and constructive comments regarding our paper. We provided a detailed description of the methodology section, covering steps such as data acquisition, data inclusion, exclusion, and preprocessing, as well as model establishment. To ensure readers have a clear understanding of our statistical analysis workflow, we utilized figures for a more concise presentation of results, such as Figures 1, 2, and 3.</p><p>3.The following references can be addressed in your study:</p><p>a.Balaha, H. M., Antar, E. R., Saafan, M. M., &#x00026; El-Gendy, E. M. (2023). A comprehensive framework towards segmenting and classifying breast cancer patients using deep learning and Aquila optimizer. Journal of Ambient Intelligence and Humanized Computing, 14(6), 7897-7917.</p><p>b.Lee, S. E., Yoon, J. H., Son, N. H., Han, K., &#x00026; Moon, H. J. (2023). Screening in Patients With Dense Breasts: Comparison of Mammography, Artificial Intelligence, and Supplementary Ultrasound. American Journal of Roentgenology.</p><p>c.Baghdadi, N. A., Malki, A., Balaha, H. M., AbdulAzeem, Y., Badawy, M., &#x00026; Elhosseini, M. (2022). Classification of breast cancer using a manta-ray foraging optimized transfer learning framework. PeerJ Computer Science, 8, e1054.</p><p>The author&#x02019;s answer: We sincerely appreciate the valuable comments. As suggested by the reviewer, we consider the references you recommended to be valuable for our research. Therefore, we have cited them in the paper (references 2, 5, and 49, respectively).</p><p>Reviewer #3</p><p>According to the corrections that were suggested by different reviewers , this article seems to be suitable for publishing.</p><p>The author&#x02019;s answer: We would like to thank you for your professional review work, and for the positive feedback.</p><p>Reviewer #5</p><p>Thanks. I didn't see the "data availability" exploitation in the manuscript. That would be good to add a statement in the manuscript to show how readers can access to the data.</p><p>The author&#x02019;s answer: We thank the reviewer for bringing this to our attention. We have appended a "data availability" statement at the end of the conclusion section and uploaded the data to Figshare. The original data can be directly accessed through the link we provided.</p><p>Reviewer #6</p><p>There have been many solutions to the previous problems. The authors should take care that the responsibility for the results and validation of the results lies with them alone. Figures and references should be carefully reviewed. The references to the equations, as well as the definitions of some of their parameters, should also be carefully checked.</p><p>The author&#x02019;s answer: We thank the reviewer for the helpful comments and appreciation of our work. We meticulously reviewed the figures, reference materials, as well as the references for equations and definitions of certain parameters, making appropriate modifications. Thanks to the reviewer for this careful comments.</p><supplementary-material id="pone.0310410.s006" position="float" content-type="local-data"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">Response to Reviewers.doc</named-content></p></caption><media xlink:href="pone.0310410.s006.doc"/></supplementary-material></body></sub-article><sub-article article-type="aggregated-review-documents" id="pone.0310410.r005" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0310410.r005</article-id><title-group><article-title>Decision Letter 2</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rabiei</surname><given-names>Reza</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Reza Rabiei</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Reza Rabiei</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0310410" id="rel-obj005" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>2</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">2 Sep 2024</named-content>
</p><p>Machine learning-based prediction of distant metastasis risk in invasive ductal carcinoma of the breast</p><p>PONE-D-23-20544R2</p><p>Dear Dr. Zhang,</p><p>We&#x02019;re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p><p>Within one week, you&#x02019;ll receive an e-mail detailing the required amendments. When these have been addressed, you&#x02019;ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p><p>An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">Editorial Manager&#x000ae;</ext-link>&#x000a0;and clicking the &#x02018;Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at <email>authorbilling@plos.org</email>.</p><p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they&#x02019;ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email>onepress@plos.org</email>.</p><p>Kind regards,</p><p>Reza Rabiei</p><p>Academic Editor</p><p>PLOS ONE</p><p>Additional Editor Comments (optional):</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>
<!-- <font color="black"> -->
<bold>Comments to the Author</bold>
</p><p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the &#x0201c;Comments to the Author&#x0201d; section, enter your conflict of interest statement in the &#x0201c;Confidential to Editor&#x0201d; section, and submit your "Accept" recommendation.<!-- </font> --></p><p>Reviewer #5:&#x000a0;All comments have been addressed</p><p>Reviewer #6:&#x000a0;All comments have been addressed</p><p>**********</p><p><!-- <font color="black"> -->2. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. <!-- </font> --></p><p>Reviewer #5:&#x000a0;Yes</p><p>Reviewer #6:&#x000a0;Yes</p><p>**********</p><p><!-- <font color="black"> -->3. Has the statistical analysis been performed appropriately and rigorously? <!-- </font> --></p><p>Reviewer #5:&#x000a0;Yes</p><p>Reviewer #6:&#x000a0;I Don't Know</p><p>**********</p><p><!-- <font color="black"> -->4. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#x02014;e.g. participant privacy or use of data from a third party&#x02014;those must be specified.<!-- </font> --></p><p>Reviewer #5:&#x000a0;Yes</p><p>Reviewer #6:&#x000a0;Yes</p><p>**********</p><p><!-- <font color="black"> -->5. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.<!-- </font> --></p><p>Reviewer #5:&#x000a0;Yes</p><p>Reviewer #6:&#x000a0;Yes</p><p>**********</p><p><!-- <font color="black"> -->6. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)<!-- </font> --></p><p>Reviewer #5:&#x000a0;Thanks for fulfilling the comments. I believe the manuscript is ready to publish in the current format.</p><p>Reviewer #6:&#x000a0;As a result of the different opinions of the referees and their comments, the article has been significantly improved and is suitable for publication.</p><p>**********</p><p><!-- <font color="black"> -->7. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#x0201c;no&#x0201d;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.<!-- </font> --></p><p>Reviewer #5:&#x000a0;No</p><p>Reviewer #6:&#x000a0;No</p><p>**********</p></body></sub-article><sub-article article-type="editor-report" id="pone.0310410.r006" specific-use="acceptance-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0310410.r006</article-id><title-group><article-title>Acceptance letter</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rabiei</surname><given-names>Reza</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Reza Rabiei</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Reza Rabiei</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0310410" id="rel-obj006" related-article-type="reviewed-article"/></front-stub><body><p>
<named-content content-type="letter-date">12 Sep 2024</named-content>
</p><p>PONE-D-23-20544R2 </p><p>PLOS ONE</p><p>Dear Dr. Zhang, </p><p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.</p><p>At this stage, our production department will prepare your paper for publication. This includes ensuring the following:</p><p>* All references, tables, and figures are properly cited</p><p>* All relevant supporting information is included in the manuscript submission,</p><p>* There are no issues that prevent the paper from being properly typeset</p><p>If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps. </p><p>Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email>onepress@plos.org</email>.</p><p>If we can help with anything else, please email us at <email>customercare@plos.org</email>.</p><p>Thank you for submitting your work to PLOS ONE and supporting open access. </p><p>Kind regards, </p><p>PLOS ONE Editorial Office Staff</p><p>on behalf of</p><p>Dr. Reza Rabiei </p><p>Academic Editor</p><p>PLOS ONE</p></body></sub-article></article>